CARA**Caraco Pharmaceuticals steigt wieder, der neue PLAYER??? - 500 Beiträge pro Seite

[js200]

10/09/2002 (12:46 ET) New 4 just released for CARA - Edgar
10/04/2002 (17:21 ET) New SB-2/A just released for CARA - Edgar
09/30/2002 (08:33 ET) Caraco Pharmaceutical Receives FDA Approval for Ticlopidine Hydrochloride - PR Newswire


JS200

[morchel]

Erfolg mit Generikern soweit ich mich erinnere!

morchel

[js200]

@MORCHEL

Die ANTWORT ist JA

company news

--------------------------------------------------------------------------------

CARA - Caraco Pharmaceutical Labs Ltd (OTCBB : CARA)

--------------------------------------------------------------------------------
Caraco Pharmaceutical Receives FDA Approval for Ticlopidine Hydrochloride

Four Additional Drugs Pending FDA Approval

MONDAY , SEPTEMBER 30, 2002 08:33 AM

DETROIT, Sep 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) has received approval from the US Food and Drug Administration (FDA) to manufacture and market ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid, Narendra N. Borkar, Chief Executive Officer, announced today.

Ticlopidine hydrochloride is a platelet aggregation inhibitor for cardiac patients. Ticlopidine hydrochloride has a US market of about $32 million. Product shipments are expected in November.

Caraco has received FDA approval for six generic drugs over the past four quarters. All six are being manufactured and marketed. These are: meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; and flurbiprofen, a generic form of Pharmacia`s Ansaid.

Aided by the extended productline, the Company recorded a 378% jump in first-half sales to a record $8.9 million, with a gross profit of $4.5 million. Year-to-date sales are running ahead of the $16 million to $18 million guidance for 2002.

Mr. Borkar noted that Caraco has four additional drugs pending FDA approval and the Company expects to receive the approval for one or two of these by yearend.

Caraco has an extensive R&D Center at its Detroit headquarters complex and receives R&D support from Sun Pharmaceutical Industries Ltd., India`s fifth largest specialty pharmaceutical firm. Sun is a major stockholder of Caraco.

Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers, distributors, drugstore chains, and healthcare systems.

This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available via EDGAR. The Company assumes no responsibility to update or clarify forward-looking statements.



MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X55573737


SOURCE Caraco Pharmaceutical Laboratories, Ltd.


CONTACT: Narendra Borkar of Caraco Pharmaceutical Laboratories, Ltd.,
[phone], [e-mail] ; or Mike Marcotte of Marcotte Financial
Relations, [phone], [e-mail], for Caraco Pharmaceutical
Laboratories, Ltd.
(CARA)

http://www.prnewswire.com



Copyright (C) 2002 PR Newswire. All rights reserved.


-0-


KEYWORD: Michigan
INDUSTRY KEYWORD: HEA
MTC
OTC
SUBJECT CODE: PDT
ERP


STOCK SYMBOLS: [(cara)]


JS200

[morchel]

Caraco Pharma ist mir seinerzeit schon positiv aufgefallen!

Die medikamente sind erprobt aber die "Schutzzeit" ist abgelaufen.

Krankenkassen müssen weltweit sparen. Warum ein teures Orginal verschreiben wenn es einen billigeren Generiker gibt!

morchel

[js200]

3:59pm ET
2.20
0.27 (13.98%)
Day`s Range: 1.93 - 2.20
Day`s Volume: 44,500
Avg. Volume: 18,172


Performance (%-changes)
1 week: 20.21%
1 month: 12.82%
1 year: 209.85%

DIESE ZAHLEN sprechen für sich

JS200

[js200]

10/22/2002 (09:13 ET) CARA: Q3 EPS 2c vs (9c), Raises FY Revenue Guidance - Knobias
10/22/2002 (09:00 ET) Caraco Pharma Posts Record Sales, First-Ever Profit - PR Newswire
10/22/2002 (08:07 ET) New 10QSB/A just released for CARA - Edgar
10/22/2002 (08:04 ET) New 10QSB just released for CARA - Edgar
10/09/2002 (12:46 ET) New 4 just released for CARA - Edgar


JS200

[js200]

company news

--------------------------------------------------------------------------------

CARA - Caraco Pharmaceutical Labs Ltd (OTCBB : CARA)

--------------------------------------------------------------------------------
Caraco Pharma Posts Record Sales, First-Ever Profit

* Q3 Sales Rise 292%, EPS Jumps to $0.02 * 9-Month Sales Rise 340%, * 2002 Sales Guidance Revised Up to $21 Million

TUESDAY , OCTOBER 22, 2002 09:00 AM

DETROIT, Oct 22, 2002 /PRNewswire-FirstCall via COMTEX/ -- Caraco Pharmaceutical Laboratories, Ltd., (OTC Bulletin Board: CARA) posted record Q3 sales and its first-ever profit, Narendra N. Borkar, Chief Executive Officer, reported today.

Third-quarter results

Net income for the quarter ended September 30, 2002 was $406,488, or $0.02 per share, a sharp turnaround from a net loss of $1,525,074, or ($0.09 per share), for 2001`s third quarter. Net sales for the third quarter rose 292% to a record $5,899,441, from $1,505,346 a year ago. Gross profit for the quarter was $2,864,102, significantly better than the $440,523 recorded the year before. Operating profit was similarly improved, rising 178% to $783,028, from a year-earlier operating loss of $1,008,371.

Nine-month results

Nine-month results were noticeably better, but included an expected net loss of $180,913, or $0.01 per share, a substantial improvement over the 9-month-2001 net loss of $5,131,857, or $0.17 per share.

Buoyed by the introduction of six new products over the trailing five quarters, net sales for the nine months rose 340% to a record $14,828,849, from $3,372,686, a year ago. Gross profit reached $7,380,041, from $468,495, for the year-earlier period. The Company posted an operating profit of $939,189, in stark contrast to an operating loss of $3,621,013, for the first nine months of 2001.

For the nine months, R&D expense was $3,792,771, including a noncash R&D charge of $1,251,200, equivalent to $0.06 per share, for two drug-technology transfers from Sun Pharmaceutical Industries, Ltd. Sun Pharma, India`s fifth largest specialty pharmaceutical firm and a major Caraco shareholder, is paid 544,000 shares of Caraco common stock for each drug technology provided to and marketed by Caraco.

Mr. Borkar said, "The third quarter was a benchmark for our Company, our employees and our shareholders. This was Caraco`s first-ever quarter of profitability. Plus, we recorded record sales for the quarter as well as the nine-month period. Nine-month-2002 sales, in fact, exceeded the Company`s combined sales from the last four years."

Mr. Borkar noted that sales were strong for the entire productline, but especially robust for three of its newer drugs: metformin hydrochloride (generic Glucophage), tramadol hydrochloride (generic Ultram), and carbamazepine hydrochloride (generic Tegretol). Sales of metroprolol tartrate (generic Lopressor) were also strong for the quarter.

Caraco has received FDA approval for eight generic drugs over the past five quarters. All eight are being manufactured and six are being marketed. These are: ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

He added, "We are optimistic about the fourth quarter, when two of our most-recently-approved FDA drugs -- ticlopidine hydrochloride and meperidine hydrochloride -- will be marketed. The combined US market for these two drugs is about $50 million.

"As a result of the dramatic sales growth, we are revising upward our sales guidance for the year to $21 million, from the earlier-announced $16 to $18 million range."

He noted that fourth-quarter results will likely include a noncash technology-transfer accounting charge for one new drug from Sun Pharma, and a noncash accounting charge related to the consummation of a new drug- development agreement between Caraco and Sun Pharma. The Company expects the noncash accounting charges for technology transfers to result in a net loss for the fourth quarter. The noncash charges do not affect the Company`s cash position or cash flow.

The Company has four drugs pending FDA approval and expects to receive the go-ahead for one or two of these by yearend. The Company also plans to file one additional drug for FDA approval by yearend.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers and distributors, drugstore chains and healthcare systems.

This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risk factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These risk factors are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Company assumes no responsibility to update or clarify forward-looking statements.



CARACO PHARMACEUTICAL LABORATORIES LIMITED
UNAUDITED STATEMENTS OF OPERATIONS

PARTICULARS NINE MONTHS ENDED THREE MONTHS ENDED
30-Sep 30-Sep
2002 2001 2002 2001
$ $ $ $

Net Sales 14,828,849 3,372,686 5,899,441 1,505,356
Cost of goods sold 7,448,809 2,904,191 3,035,340 1,064,833
Gross profit 7,380,041 468,495 2,864,102 440,523

Selling, general &
administrative expenses 2,299,631 1,772,452 990,331 623,381
R&D cost to affiliate 1,251,200 - - -
R&D cost other 2,541,449 1,934,456 969,947 697,256

Depreciation 348,571 382,599 120,795 128,258

Operating profit / (loss) 939,189 (3,621,013) 783,028 (1,008,371)

Interest
Interest expense (1,130,898) (1,524,843) (384,917) (518,500)
Interest income 10,798 14,000 8,377 1,797
Net interest expense (1,120,102) (1,510,843) (376,539) (516,703)

Net profit / (loss) (180,913) (5,131,857) 406,488 (1,525,074)

Net (loss) / income per
basic and diluted
common share (0.01) (0.17) 0.02 (0.09)

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X94122482


JS200

[js200]

company news

--------------------------------------------------------------------------------

CARA - Caraco Pharmaceutical Labs Ltd (OTCBB : CARA)

--------------------------------------------------------------------------------
CARA: Q3 EPS 2c vs (9c), Raises FY Revenue Guidance



TUESDAY , OCTOBER 22, 2002 09:13 AM

Caraco Pharmaceutical Laboratories, Ltd., (OTCBB: CARA) today reported financial results for the third quarter ended 9/30/02.

Net income for the quarter 2002 was $406,488, or $0.02 per share, a sharp turnaround from a net loss of ($1,525,074), or ($0.09 per share) , for 2001`s third quarter.

Net sales for the third quarter rose 292% to a record $5,899,441, from $1,505,346 a year ago.

GUIDANCE

Narendra N. Borkar, Chief Executive Officer, stated, "We are optimistic about the fourth quarter, when two of our most-recently-approved FDA drugs -- ticlopidine hydrochloride and meperidine hydrochloride -- will be marketed. The combined US market for these two drugs is about $50 million.

"As a result of the dramatic sales growth, we are revising upward our sales guidance for the year to $21 million, from the earlier-announced $16 to $18 million range

JS200

[js200]

3:24pm ET
2.42
0.22 (10.00%)
Day`s Range: 2.20 - 2.45
Day`s Volume: 77,800
Avg. Volume: 18,092


JS200

[js200]

Raised FY02 Revenue Guidance to $21M.

"As a result of the dramatic sales growth, we are revising upward our sales guidance for the year to $21 million, from the earlier-announced $16 to $18 million range."

Which means they expect revenue of $6.17M in Q4.

Would have liked to see Q3 revenue higher, but we are most definitely heading in the right direction.

4 drugs pending at FDA, expect 1-2 more approved by year end, will submit 1 additional drug to FDA this year.


JS200

[js200]

Von GESTERN

CARA
CARACO PHARMACEUTICAL LABS INC
2.420
+0.220 +10.00%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/21/2002 (1) days ago, when the stock price was 2.200. Since then the stock gained 10.00% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 2.420
Previous Close 2.200
Change +0.220
% Change +10.00%
Volume 80,600
Stock Activity
Open 2.210
Day`s High 2.480
Day`s Low 2.200
52 Week High 4.650
52 Week Low 0.680

Stock Price History
3 Month % Change -16.84
6 Month % Change -26.67
12 Month % Change 240.85
Stock Statistics
50 Day Close MA 2.321
200 Day Close MA 2.877
65 Day Volume MA 18,251

JS200

[Hetrade]

absolut interessanter Wert...

[js200]

@HETRADE

Dies ist auch meine Meinung

Man muss nur aufpassen zu Zeit, könnte der Kurs noch einmal korrigieren.

Das Volumen ist nicht sehr hoch, Kursverfall mit wenugen Teilen möglich.

Nachteil OTC-Wert

JS200

[js200]

company news

--------------------------------------------------------------------------------

CARA - Caraco Pharmaceutical Labs Ltd (OTCBB : CARA)

--------------------------------------------------------------------------------
VOLUME(+): CARA Volume 88% > 20-adsv, Stock +6.82%



TUESDAY , OCTOBER 22, 2002 11:16 AM

This is the 1st VOLUME alert for CARA in the past 7 calendar days.

Trading for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) has been heavier than usual in today`s session. By 11:15 ET, the stock had already traded 40,100 shares via 36 trades. The cumulative volume is 87.60% above than its 20-day average of 21,375. Normally the stock experiences around 20 individual trades per session.

So far, today`s volume surge has caused a net rise in CARA`s stock price. At the time of this alert, the stock was trading at $2.350, up $0.150 (+6.82%).

One year ago, the Company`s shares closed at $0.680. The price has gained more than 245 percent since then.

Over the last 10 trading session CARA has traded in a range between $1.720 and $2.200 and is currently trading 52.81% below its 52-week high of $4.980 set on January 22, 2002 and 245.59% above its 52-week low of $0.680 from October 29, 2001.

In the previous 3 sessions, CARA trading has displayed a positive trend. Closing results have been as follows:

October 21, 2002 --- closed at $2.200 up $0.270 (+13.99%) on 44,500 shares
October 18, 2002 --- closed at $1.930 up $0.075 (+4.04%) on 7,300 shares
October 17, 2002 --- closed at $1.855 up $0.035 (+1.92%) on 16,400 shares

The Company last released news on October 22, 2002 (today):

"Caraco Pharma Posts Record Sales, First-Ever Profit"

CARACO PHARMACEUTICAL LABS LTD
Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes nine products in 14 strengths in 33 package sizes. In 2001 the Company`s product portfolio included 12 products in 22 strengths in 36 package sizes. The Company markets all 12 products, and the Company`s drugs relate to a variety of therapeutic segments including the central nervous system, cardiology, pain management and diabetes.


JS200

[loss_pro]

aktuell schon gut bewertet. langfristler könnten aber wohl trotzdem mit dem ersten drittel einsteigen.
hab mich aber noch nicht genauer mit CARA beschäftigt.

[Hetrade]

Stimmt, das ist der Nachteil. Eine vernünftige Webpräsenz würde denen mal ganz gut tun. Das Unternehmen ist es auf jeden Fall wert, auf der Watchlist zu haben. Für mich kommt es auch positiv runter, dass die scheinbar nicht ihr erstes Augenmerk auf die Aktie, sondern auf ihre Produkte legen...

[js200]

News Headlines

Display: All typesPress ReleasesCommentary NewsGeneral News

Caraco Pharma Posts Record Sales, First-Ever Profit
22 Oct 2002, 09:01am ET (PR Newswire)

CARACO PHARMACEUTICAL LABORATORIES LTD FILES FORM 10QSB/A (CARA)
22 Oct 2002, 08:10am ET (EDGAR Online)

CARACO PHARMACEUTICAL LABORATORIES LTD FILES FORM 10QSB (CARA)
22 Oct 2002, 08:07am ET (EDGAR Online)

CARACO PHARMACEUTICAL LABORATORIES LTD FILES FORM 4 (CARA)
9 Oct 2002, 12:46pm ET (EDGAR Online)

CARACO PHARMACEUTICAL LABORATORIES LTD FILES FORM SB-2/A (CARA)
4 Oct 2002, 5:22pm ET (EDGAR Online)

Caraco Pharmaceutical Receives FDA Approval for Ticlopidine Hydrochloride
30 Sep 2002, 08:34am ET (PR Newswire)

CARACO PHARMACEUTICAL LABORATORIES LTD FILES FORM SB-2/A (CARA)
4 Sep 2002, 5:23pm ET (EDGAR Online)

Caraco Pharmaceutical Receives FDA Approval for Meperidine Hydrochloride
13 Aug 2002, 08:32am ET (PR Newswire)

CARACO PHARMACEUTICAL LABORATORIES LTD FILES FORM 10QSB (CARA)
22 Jul 2002, 08:02am ET (EDGAR Online)

Caraco Pharmaceutical Q2 Sales Soar 509
21 Jul 2002, 7:00pm ET (PR Newswire)

CARACO PHARMACEUTICAL LABORATORIES LTD FILES FORM SB-2 (CARA)
3 Jul 2002, 5:11pm ET (EDGAR Online)

JS200

[Hetrade]

positiv rüber meine ich natürlich...

[js200]

DIESE ZAHLEN SPRECHEN FÜR SICH

1 week: 32.96%
1 month: 35.19%
1 year: 255.88%


JS200

[js200]

12:09pm ET
2.54
0.12 (4.95%)
Day`s Range: 2.46 - 2.55
Day`s Volume: 27,100
Avg. Volume: 18,251

JS200

[Hetrade]

nicht schlecht...

[js200]

3:29pm ET
2.60
0.18 (7.43%)
Day`s Range: 2.46 - 2.60
Day`s Volume: 33,900
Avg. Volume: 18,251


JS200

[js200]

3:53pm ET
2.55
0.13 (5.37%)
Day`s Range: 2.46 - 2.60
Day`s Volume: 39,900
Avg. Volume: 18,251

JS200

[js200]

3:46pm ET
2.70
0.15 (5.88%)
Day`s Range: 2.50 - 2.75
Day`s Volume: 41,100
Avg. Volume: 18,417


JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.700
+0.150 +5.88%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY :recommendation was made on 10/21/2002 (3) days ago, when the stock price was 2.200. Since then the stock gained 22.73% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is extremely high. The security price is trending up: and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 2.700
Previous Close 2.550
Change +0.150
% Change +5.88%
Volume 41,100
Stock Activity
Open 2.600
Day`s High 2.750
Day`s Low 2.500
52 Week High 4.650
52 Week Low 0.690

Stock Price History
3 Month % Change 1.89
6 Month % Change -16.41
12 Month % Change 275.00
Stock Statistics
50 Day Close MA 2.316
200 Day Close MA 2.877
65 Day Volume MA 18,145

JS200

[JS222]

11:27am ET
2.65
0.02 (0.76%)
Day`s Range: 2.60 - 2.73
Day`s Volume: 15,600
Avg. Volume: 0


JS200

[JS222]

Von GESTERN

CARA
CARACO PHARMACEUTICAL LABS INC
2.540
-0.090 -3.42%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/21/2002 (7) days ago, when the stock price was 2.200. Since then the stock gained 15.45% .

Today the stock closed lower, close to its low (sign of weakness) with a higher high and a lower low (sign of increase in volatility). The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 2.540
Previous Close 2.630
Change -0.090
% Change -3.42%
Volume 37,700
Stock Activity
Open 2.650
Day`s High 2.730
Day`s Low 2.520
52 Week High 4.650
52 Week Low 0.690

Stock Price History
3 Month % Change -6.96
6 Month % Change -16.72
12 Month % Change 238.67
Stock Statistics
50 Day Close MA 2.310
200 Day Close MA 2.876
65 Day Volume MA 18,582

JS200

[JS222]

Caraco Pharmaceutical Reports Detroit EDC Board Approves Loan Restructure
via COMTEX

October 29, 2002

DETROIT, Oct 29, 2002 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd., (OTC Bulletin Board: CARA) reported today that the Board of Directors of the Economic Development Corporation of the City of Detroit has passed a resolution to approve the restructuring of its mortgage loan, Narendra N. Borkar, Chief Executive Officer, reported today.

According to the terms of the revised agreement, the $7.8 million loan to Caraco will carry a graduated interest rate beginning at 2.75% for the first year and increasing to 5.16% for the sixth and final year.

The revised mortgage loan will be effective only after both parties have signed the agreement.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers, distributors, drugstore chains and healthcare systems.

Make Your Opinion Count - Click Here http://tbutton.prnewswire.com/prn/11690X67852077

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CARA)

Copyright (C) 2002 PR Newswire. All rights reserved.

JS200

[JS222]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.510
-0.040 -1.57%


Daily Commentary
SELL

Our system recommends SELL as of today. Previous BUY recommendation was made on 10/21/2002 (9) days ago, when the stock price was 2.200. Since then the stock gained 14.09% .

Today the stock closed lower, at its low (sign of weakness) with a lower high and a lower low. The volume is extremely low. The security price is trending up.

Long-term trend is bearish, and the upward move seems to have stopped. An early correction has started which may shortly turn into a bear trap. You may sell this stock now, but be careful!

Candlestick Analysis

Today’s Candlestick Patterns:
Black Candlestick

Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.

Stock Quote
Last 2.510
Previous Close 2.550
Change -0.040
% Change -1.57%
Volume 1,600
Stock Activity
Open 2.570
Day`s High 2.570
Day`s Low 2.510
52 Week High 4.650
52 Week Low 0.690

Stock Price History
3 Month % Change -9.39
6 Month % Change -16.33
12 Month % Change 234.67
Stock Statistics
50 Day Close MA 2.302
200 Day Close MA 2.866
65 Day Volume MA 18,828

JS200

[JS222]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.570
+0.060 +2.39%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/31/2002 (0) days ago, when the stock price was 2.570. Since then the stock gained 0.00% .

Today the stock closed higher, at its high (sign of strength) with an unchanged high and a lower low. The volume is normal. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Short White Candlestick

Today a Short White Candlestick formed. There was a limited price change that may represent consolidation.

Stock Quote
Last 2.570
Previous Close 2.510
Change +0.060
% Change +2.39%
Volume 18,100
Stock Activity
Open 2.540
Day`s High 2.570
Day`s Low 2.500
52 Week High 4.650
52 Week Low 0.690

Stock Price History
3 Month % Change -6.55
6 Month % Change -14.33
12 Month % Change 267.14
Stock Statistics
50 Day Close MA 2.298
200 Day Close MA 2.860
65 Day Volume MA 19,018

JS200

[js200]

Caraco Pharmaceutical Receives FDA Approval for Clozapine
via COMTEX

November 18, 2002

DETROIT, Nov 18, 2002 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) has received approval from the US Food and Drug Administration (FDA) to manufacture and market clozapine, a generic form of Novartis`Clozaril, Narendra N. Borkar, Chief Executive Officer, reported today.

Clozapine is prescribed for the treatment of schizophrenia and has a US market of about $230 million.

In addition to clozapine, Caraco has received FDA approval for eight generic drugs over the past five quarters. These are: ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis`Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Aided by the introduction of new products, the Company last month reported record Q3 and 9-month sales and its first-ever profit for a quarter. As a result, the Company revised upward its sales guidance for 2002 to $21 million, from the earlier-announced $16 to 18 million range.

Mr. Borkar said the Company has three drugs pending FDA approval and expects to receive the go-ahead for one of these by yearend. He noted that the Company plans to file one additional drug for FDA approval by yearend.

Caraco has an extensive R&D Center at its Detroit headquarters complex and receives R&D support from Sun Pharmaceutical Industries Ltd., India`s fifth largest pharmaceutical firm. Sun Pharma is a major stockholder of Caraco.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers and distributors, drugstore chains and healthcare systems.

This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risk factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These risk factors and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Company assumes no responsibility to update or clarify forward-looking statements.

Make Your Opinion Count - Click Here http://tbutton.prnewswire.com/prn/11690X13312372

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CARA)

Copyright (C) 2002 PR Newswire. All rights reserved


JS200

[js200]

11/18/2002 (15:12 ET) PR: Caraco Receives FDA Approval for Clozapine - Knobias
11/18/2002 (15:03 ET) Caraco Gets FDA Clearance - Knobias
11/18/2002 (15:01 ET) Caraco Pharmaceutical Receives FDA Approval for Clozapine - PR Newswire
10/29/2002 (10:00 ET) Caraco Pharmaceutical Reports Detroit EDC Board Approves Loan Restructure - PR Newswire
10/22/2002 (11:16 ET) VOLUME(+): CARA Volume 88% > 20-adsv, Stock +6.82% - Knobias


JS200

[js200]

company news

--------------------------------------------------------------------------------

CARA - Caraco Pharmaceutical Labs Ltd (OTCBB : CARA)

--------------------------------------------------------------------------------
Caraco awarded FDA approval for generic schizophrenia drug



TUESDAY , NOVEMBER 19, 2002 07:16 AM

Nov 19, 2002 (Datamonitor via COMTEX) -- Caraco Pharmaceutical Laboratories has received approval from the FDA to manufacture and market clozapine, a generic form of Novartis` Clozaril.

Clozapine is prescribed for the treatment of schizophrenia and has a US market of about $230 million.



URL: http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon


Copyright (C) 2002 Datamonitor. All rights reserved


-0-


KEYWORD: United States
SUBJECT CODE: CNS, Psychosis
Generics
Big Pharma
Novartis AG

JS200

[js200]

11/20/2002 (03:43 ET) India`s Sun Pharma receives US FDA approval for Clozapine -
11/20/2002 (01:20 ET) ARM OF INDIA`S SUN PHARMA RECEIVES FDA NOD FOR SCHIZOPHRENIA DRUG - AsiaPulse Pte. Ltd.
11/19/2002 (07:16 ET) Caraco awarded FDA approval for generic schizophrenia drug - Datamonitor
11/18/2002 (15:12 ET) PR: Caraco Receives FDA Approval for Clozapine - Knobias
11/18/2002 (15:03 ET) Caraco Gets FDA Clearance - Knobias


JS200

[js200]

3:27pm ET
2.74
0.18 (7.03%)
Day`s Range: 2.55 - 2.74
Day`s Volume: 23,400
Avg. Volume: 17,822

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.740
+0.180 +7.03%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/31/2002 (21) days ago, when the stock price was 2.570. Since then the stock gained 6.61% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and the buying pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 2.740
Previous Close 2.560
Change +0.180
% Change +7.03%
Volume 25,400
Stock Activity
Open 2.580
Day`s High 2.740
Day`s Low 2.550
52 Week High 4.650
52 Week Low 0.900

Stock Price History
3 Month % Change 0.00
6 Month % Change -11.90
12 Month % Change 204.44
Stock Statistics
50 Day Close MA 2.231
200 Day Close MA 2.777
65 Day Volume MA 18,118

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.730
-0.010 -0.36%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/31/2002 (22) days ago, when the stock price was 2.570. Since then the stock gained 6.23% .

Today the stock closed lower, close to its high (sign of strength) with an unchanged high and a higher low. The volume is extremely low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 2.730
Previous Close 2.740
Change -0.010
% Change -0.36%
Volume 8,700
Stock Activity
Open 2.740
Day`s High 2.740
Day`s Low 2.680
52 Week High 4.650
52 Week Low 0.900

Stock Price History
3 Month % Change -1.44
6 Month % Change -13.33
12 Month % Change 203.33
Stock Statistics
50 Day Close MA 2.232
200 Day Close MA 2.776
65 Day Volume MA 18,094

JS200

[js200]

Heftiger Widerstand die 2,65 Dollar, könnten nächstens fallen
Last Trade: 2.650 Change: 0.000 (+0.000%)
Previous Close: 2.650 Volume: 1,100
Bid: 2.630 Ask: 2.650


Leider sehr weniger Umsatz, der grosse NACHTEIL

Aber die Leistung ist schon gut
Performance (%-changes)
1 week: 3.28%
1 month: 3.11%
1 year: 178.94%

JS200

[js200]

Caraco Pharma Signs New R&D Agreement for 25 New Drugs
via COMTEX

December 3, 2002

DETROIT, Dec 3, 2002 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories Ltd. (OTC Bulletin Board: CARA) signed an R&D agreement, which has been approved by its independent Directors, for development of up to 25 new generic drugs, with Sun Pharma Global Inc. (Sun Global), a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd (Sun Pharma), Narendra N. Borkar, Chief Executive Officer, announced today.

Detroit based Caraco Pharmaceutical Laboratories Ltd. develops, manufactures and distributes generic prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains and healthcare systems. Sun Pharma (Reuters: Sun.BO), a major Caraco stockholder, is India`s fifth largest pharmaceutical company. Sun Pharma operates eight manufacturing locations and two world class R&D Centers in India. A public company, Sun Pharma is ranked among India`s top 50 companies by market cap and holds a leading rank among specialty customers such as psychiatrists, cardiologists, neurologists, etc. in the country.

The key purpose of the new agreement is to provide for direct transfer of R&D-based intellectual property in the form of drug technologies to Caraco, in order to quickly and efficiently expand Caraco`s product line.

According to terms of the agreement, Sun Global will provide up to 25 new generic drugs to Caraco over a five-year period. In return, Sun Global will receive 544,000 shares of a newly created preferred Caraco stock for each new drug transferred. These preferred shares are convertible after three years, on one-to-one basis, to Rule 144 common shares.

Under a previous agreement with Sun Pharma, Caraco received technology for two DESI products and 11 ANDA products from Sun Pharma and has received FDA approval for seven of these generic drugs over the past five quarters. These are clozapine, a generic form of Novartis`Clozaril; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram; and ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid.

Buoyed by the introduction of new products, Caraco reported record third- quarter sales and the Company`s first ever net profit. It raised its sales guidance from $16-18 million to $21 million for calendar year 2002.

The Company has four drugs pending FDA approval and expects to receive the go-ahead to market one of these by year-end.

Mr. Borkar said, `This is a decidedly accretive step for our Company and shareholders. The new R&D agreement is expected to provide us with the resources and platform to expand our product line, grow sales, and improve our earnings picture.`

This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risk factors and uncertainties which could cause results to differ materially from those described in the forward-looking statements. These risk factors are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Company assumes no responsibility to update or clarify forward looking statements.

MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X35845738

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar of Caraco Pharmaceutical Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CARA)

Copyright (C) 2002 PR Newswire. All rights reserved.

JS200

[js200]

12/03/2002 (08:00 ET) Caraco Pharma Signs New R&D Agreement for 25 New Drugs - PR Newswire
11/20/2002 (03:43 ET) India`s Sun Pharma receives US FDA approval for Clozapine -
11/20/2002 (01:20 ET) ARM OF INDIA`S SUN PHARMA RECEIVES FDA NOD FOR SCHIZOPHRENIA DRUG - AsiaPulse Pte. Ltd.
11/19/2002 (07:16 ET) Caraco awarded FDA approval for generic schizophrenia drug - Datamonitor
11/18/2002 (15:12 ET) PR: Caraco Receives FDA Approval for Clozapine - Knobias


JS200

[loss_pro]

ja, wird langsam zeit zu kaufen...
aber was sind das für drugs? nur eine mio pro stück? is das nich nen bißchen wenig?

[js200]

@LOSS_PRO

Und , hast du ?????

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.730
+0.160 +6.23%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/31/2002 (33) days ago, when the stock price was 2.570. Since then the stock gained 6.23% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 2.730
Previous Close 2.570
Change +0.160
% Change +6.23%
Volume 25,700
Stock Activity
Open 2.580
Day`s High 2.740
Day`s Low 2.580
52 Week High 4.650
52 Week Low 0.900

Stock Price History
3 Month % Change 1.87
6 Month % Change 0.00
12 Month % Change 196.74
Stock Statistics
50 Day Close MA 2.264
200 Day Close MA 2.761
65 Day Volume MA 18,351

JS200

[js200]

Mühsam ernährt sich das Eichhörnchen, aber die Reserve wird angelegt

CARACO PHARM LABS LTD - OTC BB: CARA

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time

Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
2.75 0.02 (0.73) 2.72 (5) 2.77 (5) 15:59
Day Volume Last Size Open High Low
13,500 500 2.71 2.75 2.70
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+++ 13 1,038 4.9844 0.9063
Prev Close VWAP Avg Day Vol
2.73 2.7323 N/A

JS200

[js200]

@NEONO

Beobachten
Cara Pharmaceutical Labs OTCBB:CARA
Danke JS200, sehr interessante Firma.

Aus CARA kann was werden, nur man braucht Zeit, genauso wie bei LAMP

JS200

[js200]

CARACO PHARM LABS LTD - OTC BB: CARA

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time

Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
2.70 0.08 (3.05) 2.65 (5) 2.70 (5) 15:05
Day Volume Last Size Open High Low
10,300 1,000 2.68 2.70 2.65
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
++-+ 11 936 4.9844 0.9063
Prev Close VWAP Avg Day Vol
2.62 2.6751 N/A

JS200

[js200]

[js200]

Research and Markets Ltd: The 100 Major Manufacturing Firms -- Drugs - Generic
via COMTEX

December 17, 2002

Dec 17, 2002 (M2 PRESSWIRE via COMTEX) --

Full profile information on 100 major manufacturing firms in the Drugs - Generic industry. Includes detailed contact information, decision-makers, SIC and NAICS codes and other specialized fields of information. File contains both a PDF report for viewing individual company profiles and a CSV table for spreadsheet programs and downloading.

Companies within this SIC/NAICS code: Able Laboratories, Inc., Alpharma Inc., Amarin Corporation plc, American Pharmaceutical Partners, Inc., Barr Laboratories, Inc., Caraco Pharmaceutical Laboratories, Ltd., Eon Labs, Inc., Faulding Pharmaceuticals, GeneMedix Plc, Geneva Pharmaceuticals, Inc., Halsey Drug Co., Inc., Hi-Tech Pharmacal Co., Inc., Impax Laboratories, Inc., IVAX Corporation, KV Pharmaceutical Company, Lannett Company, Inc., Mylan Laboratories Inc., Perrigo Company, Pharmaceutical Formulations, Inc., Pharmaceutical Resources, Inc., SkyePharma PLC, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Watson Pharmaceuticals, Inc.

Associated Industries: Drugs - Generic

Keywords: drugs, pharmaceuticals, medicine, generic, non-prescription

For a complete index of this report click on http://www.researchandmarkets.com/reports/3046" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3046

Get full profile information on 100 major manufacturing firms in the Drugs - Generic Industry. Full profiles include detailed contact information (phone and fax numbers, addresses, etc..) company information fields, (headquarters, ownership, year established, foreign trade, stock ticker) decision makers, SIC and NAICS codes and more. This file contains both a PDF document (Adobe Acrobat) for viewing individual company profiles, as well as a CSV (comma delimited) table for use in spreadsheet programs, or for downloading into databases and contact management systems. Use profiles for prospecting leads, target marketing or market research. All information provided by Harris InfoSource, the leading compiler of information on the manufacturing and technology sectors.

Report Pricing:

Electronic EUR 37 (US$ 35).

ORDERING INFORMATION - FIVE EASY WAYS TO PLACE YOUR ORDER:

ORDER ONLINE: To order this report please click on http://www.researchandmarkets.com/reports/3046" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3046 ORDER VIA EMAIL: mailto:[e-mail] ORDER VIA FAX-BACK FORM: Click on http://www.researchandmarkets.com/reports/3046" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3046 Fax to [phone] ORDER VIA POST: Click on http://www.researchandmarkets.com/reports/3046" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3046 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland ORDER VIA PHONE: Telephone: [phone]

About Research and Markets Ltd.

Research and Markets Ltd. are Europe`s largest resource for market research. R&M distribute thousands of major research publications from the world`s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or [e-mail]

CONTACT: Holly Swift, Public Relations Manager, Research, Research and Markets Ltd. e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2002 M2 COMMUNICATIONS LTD


JS200

[JS222]

Unsere CARA hält sich wacker!!!!!!

JS200

[JS222]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.650
+0.050 +1.92%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/31/2002 (60) days ago, when the stock price was 2.570. Since then the stock gained 3.11% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a lower low (sign of increase in volatility). The volume is low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Short White Candlestick

Today a Short White Candlestick formed. There was a limited price change that may represent consolidation.

Stock Quote
Last 2.650
Previous Close 2.600
Change +0.050
% Change +1.92%
Volume 11,200
Stock Activity
Open 2.640
Day`s High 2.650
Day`s Low 2.520
52 Week High 4.650
52 Week Low 1.150

Stock Price History
3 Month % Change 39.47
6 Month % Change -12.54
12 Month % Change 130.43
Stock Statistics
50 Day Close MA 2.551
200 Day Close MA 2.720
65 Day Volume MA 17,034

JS200

[JS222]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.670
+0.020 +0.75%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/31/2002 (61) days ago, when the stock price was 2.570. Since then the stock gained 3.89% .

Today the stock closed higher, at its high (sign of strength) with a higher high and an unchanged low. The volume is low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Short White Candlestick

Today a Short White Candlestick formed. There was a limited price change that may represent consolidation.

Stock Quote
Last 2.670
Previous Close 2.650
Change +0.020
% Change +0.75%
Volume 13,100
Stock Activity
Open 2.650
Day`s High 2.670
Day`s Low 2.520
52 Week High 4.650
52 Week Low 1.150

Stock Price History
3 Month % Change 40.53
6 Month % Change -11.88
12 Month % Change 132.17
Stock Statistics
50 Day Close MA 2.566
200 Day Close MA 2.717
65 Day Volume MA 17,003

JS200

[JS222]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.700
-0.040 -1.46%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 10/31/2002 (64) days ago, when the stock price was 2.570. Since then the stock gained 5.06% .

Today the stock closed lower, at its low (sign of weakness) with an unchanged high and a higher low. The volume is extremely low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Gravestone Doji

Today a Gravestone Doji formed. Buyers dominated trading and drove prices higher during the session. However, by the end of the session, sellers resurfaced and pushed prices back to the opening level and the session low. Be careful, this may be a sign of a potential bullish reversal or bottom!

Stock Quote
Last 2.700
Previous Close 2.740
Change -0.040
% Change -1.46%
Volume 3,500
Stock Activity
Open 2.700
Day`s High 2.740
Day`s Low 2.700
52 Week High 4.650
52 Week Low 1.560


Stock Price History
3 Month % Change 54.29
6 Month % Change -6.90
12 Month % Change 73.08
Stock Statistics
50 Day Close MA 2.583
200 Day Close MA 2.711
65 Day Volume MA 16,992

JS200

[js200]

Research and Markets: Drugs - Generic Value Set
via COMTEX

January 6, 2003

Jan 06, 2003 (M2 PRESSWIRE via COMTEX) --

Get both an Industry Report and 100 full profiles on major manufacturing firms in the Drugs - Generic industry. The Value Set combines the Industry Report and the 100 Major Firm Profiles collection at a better value than buying them separately. Receive both a unique perspective on your target industry as well as detailed profile information on 100 major manufacturing companies in the industry.

Companies within this SIC/NAICS code: Able Laboratories, Inc., Alpharma Inc., Amarin Corporation plc, American Pharmaceutical Partners, Inc., Barr Laboratories, Inc., Caraco Pharmaceutical Laboratories, Ltd., Eon Labs, Inc., Faulding Pharmaceuticals, GeneMedix Plc, Geneva Pharmaceuticals, Inc., Halsey Drug Co., Inc., Hi-Tech Pharmacal Co., Inc., Impax Laboratories, Inc., IVAX Corporation, KV Pharmaceutical Company, Lannett Company, Inc., Mylan Laboratories Inc., Perrigo Company, Pharmaceutical Formulations, Inc., Pharmaceutical Resources, Inc., SkyePharma PLC, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Watson Pharmaceuticals, Inc.

Associated Industries: Drugs - Generic

Keywords: drugs, pharmaceuticals, medicine, generic, non-prescription

For a complete index of this report click on http://www.researchandmarkets.com/reports/3045" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3045

Get two great resources at a value. First, receive a quick but informative guide to the U.S. Drugs - Generic industry. Learn about industry firm count and employment, geographical areas of growth, SIC and NAICS codes comprising the industry, and see a list of major companies in the industry. Second, get full profile information on 100 major manufacturing firms in the industry. Full profiles include detailed contact information (phone and fax numbers, addresses, etc..) company information fields, (headquarters, ownership, year established, foreign trade, stock ticker) decision makers, SIC and NAICS codes and more. This file contains the Industry Report and Major 100 Manufacturers in PDF format, as well as the Major 100 Manufacturers in a CSV (comma delimited) table for use in spreadsheet programs, or for downloading into databases and contact management systems. Use reports and profiles for prospecting leads, target marketing or market research. All information provided by Harris InfoSource, the leading compiler of information on the manufacturing and technology sectors.

Report Pricing:

Electronic EUR 46 (US$ 43).

ORDERING INFORMATION - FIVE EASY WAYS TO PLACE YOUR ORDER:

ORDER ONLINE: To order this report please click on http://www.researchandmarkets.com/reports/3045" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3045 ORDER VIA EMAIL: mailto:[e-mail] ORDER VIA FAX-BACK FORM: Click on http://www.researchandmarkets.com/reports/3045" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3045 Fax to [phone] ORDER VIA POST: Click on http://www.researchandmarkets.com/reports/3045" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/3045 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland ORDER VIA PHONE: Telephone: [phone]

About Research and Markets Ltd.

Research and Markets Ltd. are Europe`s largest resource for market research. R&M distribute thousands of major research publications from the world`s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or [e-mail]

CONTACT: Holly Swift, Public Relations Manager, Research, Research and Markets Ltd. e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

JS200

[js200]

http://screen.yahoo.com/d?vw=0&db=reports&z=dat&tk=cara.ob

JS200

[js200]

Ist morgen der Tag des Durchbruchs der 2,80 ??????

3:58pm ET
2.80
0.09 (3.32%)
Day`s Range: 2.615 - 2.80
Day`s Volume: 24,100
Avg. Volume: 16,343

Hält sich wacker

1 week: 4.47%
1 month: 5.26%
1 year: 17.64%


JS200

[js200]

Es war der Tag XXXX

Last Trade: 3.010 Change: 0.210 (+7.500%)
Previous Close: 2.800 Volume: 61,100
Bid: 2.980 Ask: 3.010
Today`s Open: 2.830 # of Trades: 64

--------------------------------------------------------------------------------

Day High: 3.010 Day Low: 2.650
52 Week High: 4.980 52 week Low: 1.720
Market Cap: 68.97M Avg Daily Vol: 15,200
EPS: -0.06 PE Ratio: -50.167
Dividend: N/A Yield: N/A

JS200

[fonx]

Wer war denn bei 0.20 schon dabei????????? Fonx

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.010
+0.210 +7.50%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 1/15/2003 (0) days ago, when the stock price was 3.010. Since then the stock gained 0.00% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 3.010
Previous Close 2.800
Change +0.210
% Change +7.50%
Volume 61,100
Stock Activity
Open 2.830
Day`s High 3.010
Day`s Low 2.650
52 Week High 4.650
52 Week Low 1.750

Stock Price History
3 Month % Change 60.11
6 Month % Change 7.50
12 Month % Change -20.16
Stock Statistics
50 Day Close MA 2.610
200 Day Close MA 2.671
65 Day Volume MA 17,725

JS200

[js200]

@HETRADE

Noch immer dabei ????????

JS200

[js200]

CARA - CARACO PHARMACEUTICAL LABS LTD Company Profile

Last
Sale:
-
Best
Bid:
2.98
Best Bid
Depth:
500
Best
Ask:
3.01
Best Ask
Depth:
500

MPID Bid Size Ask Size U O/C
WIEN 2.98 500 3.01 500 O
PRGM 2.8 500 3.05 500 O
BPAT 2.75 500 3.08 500 O
NITE 2.79 500 3.09 500 O
BMIC 2 500 3.1 500 O
FAHN 2.87 500 3.1 500 O
HILL 2.85 500 3.1 500 O
MOKE 2.54 500 3.1 500 O
TDCM 2.95 500 3.1 500 O


JS200

[js200]

Cara Open Gap von 2.3 %

JS200

[js200]

Ausbruch bestätigt

10:33am ET
3.35
0.34 (11.29%)
Day`s Range: 3.05 - 3.42
Day`s Volume: 26,200
Avg. Volume: 17,511

JS200

[fonx]

http://quotes.barchart.com/texpert.asp?sym=cara

[js200]

CARA - CARACO PHARM LAB (OTCBB)

Date Open High Low Last Change Volume % Change
01/16/03 3.08 3.42 3.05 3.38 +0.37 97900 +12.29 %

JS200

[js200]

company news

--------------------------------------------------------------------------------

CARA - Caraco Pharmaceutical Labs Ltd (OTCBB : CARA)

--------------------------------------------------------------------------------
VOLUME(+): CARA Volume 74% > 20-adsv, Stock +11.96%



THURSDAY , JANUARY 16, 2003 10:21 AM

This is the 1st VOLUME alert for CARA in the past 7 calendar days.

Trading for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) has been heavier than usual in today`s session. By 10:20 ET, the stock had already traded 30,400 shares via 45 trades. The cumulative volume is 74.31% above than its 20-day average of 17,440. Normally the stock experiences around 14 individual trades per session.

So far, today`s volume surge has caused a net rise in CARA`s stock price. At the time of this alert, the stock was trading at $3.370, up $0.360 (+11.96%).

One year ago, the Company`s shares closed at $3.800. The price has declined more than 11 percent since then.

Over the last 10 trading session CARA has traded in a range between $2.520 and $3.010 and is currently trading 32.33% below its 52-week high of $4.980 set on January 22, 2002 and 95.93% above its 52-week low of $1.720 from October 07, 2002.

In the previous 3 sessions, CARA trading has displayed a positive trend. Closing results have been as follows:

January 15, 2003 --- closed at $3.010 up $0.210 (+7.50%) on 61,100 shares
January 14, 2003 --- closed at $2.800 up $0.090 (+3.32%) on 28,500 shares
January 13, 2003 --- closed at $2.710 up $0.020 (+0.74%) on 3,500 shares

The Company last released news on December 03, 2002:

"Caraco Pharma Signs New R&D Agreement for 25 New Drugs"

CARACO PHARMACEUTICAL LABS LTD
Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes nine products in 14 strengths in 33 package sizes. In 2001 the Company`s product portfolio included 12 products in 22 strengths in 36 package sizes. The Company markets all 12 products, and the Company`s drugs relate to a variety of therapeutic segments including the central nervous system, cardiology, pain management and diabetes.


JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.380
+0.370 +12.29%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 1/15/2003 (1) days ago, when the stock price was 3.010. Since then the stock gained 12.29% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 3.380
Previous Close 3.010
Change +0.370
% Change +12.29%
Volume 99,000
Stock Activity
Open 3.080
Day`s High 3.420
Day`s Low 3.050
52 Week High 4.650
52 Week Low 1.750

Stock Price History
3 Month % Change 85.71
6 Month % Change 19.86
12 Month % Change -7.40
Stock Statistics
50 Day Close MA 2.627
200 Day Close MA 2.670
65 Day Volume MA 19,172

JS200

[js200]

01/16/2003 (10:21 ET) VOLUME(+): CARA Volume 74% > 20-adsv, Stock +11.96% - Knobias
01/06/2003 (06:53 ET) Research and Markets: Drugs - Generic Value Set - M2 Communications

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.300
-0.080 -2.37%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 1/15/2003 (2) days ago, when the stock price was 3.010. Since then the stock gained 9.63% .

Today the stock closed lower, at its low (sign of weakness) with a higher high and a higher low. The volume is high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 3.300
Previous Close 3.380
Change -0.080
% Change -2.37%
Volume 31,800
Stock Activity
Open 3.430
Day`s High 3.500
Day`s Low 3.300
52 Week High 4.650
52 Week Low 1.750

Stock Price History
3 Month % Change 77.90
6 Month % Change 14.58
12 Month % Change -13.16
Stock Statistics
50 Day Close MA 2.643
200 Day Close MA 2.668
65 Day Volume MA 19,458

JS200

[fonx]

http://quotes.barchart.com/texpert.asp?sym=cara

[fonx]

http://www.caraco.com/

[js200]

Von Gestern
CARA
CARACO PHARMACEUTICAL LABS INC
3.340
+0.080 +2.45%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 1/27/2003 (0) days ago, when the stock price was 3.340. Since then the stock gained 0.00% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a lower low (sign of increase in volatility). The volume is high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 3.340
Previous Close 3.260
Change +0.080
% Change +2.45%
Volume 27,300
Stock Activity
Open 3.250
Day`s High 3.340
Day`s Low 3.210
52 Week High 3.960
52 Week Low 1.750

Stock Price History
3 Month % Change 31.50
6 Month % Change 22.34
12 Month % Change -1.76
Stock Statistics
50 Day Close MA 2.721
200 Day Close MA 2.667
65 Day Volume MA 18,857

JS200

[js200]

Da kommen auch keine News mehr, aber immerhin 50%

01/16/2003 (10:21 ET) VOLUME(+): CARA Volume 74% > 20-adsv, Stock +11.96% - Knobias
01/06/2003 (06:53 ET) Research and Markets: Drugs - Generic Value Set - M2 Communications


JS200

[js200]

Macht immer mehr Freude

Caraco Pharm Labs - OTC BB: CARA

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time

Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
3.69 0.26 (7.58) 3.65 (5) 3.69 (5) 14:23
Day Volume Last Size Open High Low
76,700 500 3.45 3.70 3.45
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-+ 81 947 4.1094 N/A
Prev Close VWAP Avg Day Vol
3.43 3.5838 N/A

JS200

[Neono]

Ewige Dankbarkeit ist Dir sicher





Neono

[js200]

company news

--------------------------------------------------------------------------------

CARA - Caraco Pharmaceutical Labs Ltd (OTCBB : CARA)

--------------------------------------------------------------------------------
Caraco Pharmaceutical Receives FDA Approval for Digoxin

Two Additional Drugs Pending FDA Approval

MONDAY , FEBRUARY 03, 2003 02:24 PM

DETROIT, Feb 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Caraco Pharmaceutical Laboratories, Ltd., (OTC Bulletin Board: CARA) has received approval from the US Food and Drug Administration (FDA) to manufacture and market digoxin, a generic form of Glaxo Wellcome`s Lanoxin, Narendra N. Borkar, Chief Executive Officer, announced today.

Digoxin is prescribed for the treatment of mild to moderate cardiac failure and has a US market of about $155 million. Caraco will produce digoxin in two strengths, 0.125 mgm and 0.25 mgm.

In addition to digoxin, Caraco has received FDA approval for nine generic drugs over the past six quarters. These are: clozapine, a generic form of Novartis` Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi- Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Mr. Borkar said the Company has three additional drugs pending FDA approval and expects to receive approval for these by yearend. He noted that the Company plans to file four new generic-drug applications with the FDA this year.

Caraco has an extensive R&D Center at its Detroit headquarters complex and receives R&D support from Sun Pharmaceutical Industries Ltd., India`s fifth largest pharmaceutical firm. Caraco and Sun last year signed a new five-year R&D agreement which calls for the development by Sun of up to 25 new generic drugs. Sun is a major stockholder of Caraco.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers, distributors, drugstore chains and healthcare systems.

This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risk factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These risk factors and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Company assumes no responsibility to update or clarify forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.



CONTACT: Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical
Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial
Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd.
(CARA)

http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: Michigan
INDUSTRY KEYWORD: MTC
OTC


STOCK SYMBOLS: [(cara)]


JS200

[js200]

02/03/2003 (14:24 ET) Caraco Pharmaceutical Receives FDA Approval for Digoxin - PR Newswire
02/03/2003 (11:21 ET) VOLUME(+): CARA Volume 56% > 20-adsv, Stock +4.66% - Knobias
01/16/2003 (10:21 ET) VOLUME(+): CARA Volume 74% > 20-adsv, Stock +11.96% - Knobias
01/06/2003 (06:53 ET) Research and Markets: Drugs - Generic Value Set - M2 Communications


JS200

[MRASTA]

und es kommt noch besser !!!!

Wenn ich nicht CARA hätte, würde ich bei LAMP verzweifeln, aber so, geht es mir prima.

Caraco Pharmaceutical Receives FDA Approval for Digoxin
3 Feb 2003, 2:24pm ET

- - - - -

/FROM PR NEWSWIRE DETROIT 248-352-5200/
[STK] CARA
[IN] MTC OTC
[SU]
TO BUSINESS AND MEDICAL EDITORS:

Caraco Pharmaceutical Receives FDA Approval for Digoxin

Two Additional Drugs Pending FDA Approval

DETROIT, Feb. 3 /PRNewswire-FirstCall/ --
Caraco Pharmaceutical Laboratories, Ltd., (BB:CARA) has
received approval from the US Food and Drug Administration (FDA) to manufacture and market digoxin, a generic form of Glaxo Wellcome`s Lanoxin, Narendra N. Borkar, Chief Executive Officer, announced today.

Digoxin is prescribed for the treatment of mild to moderate cardiac failure and has a US market of about $155 million. Caraco will produce digoxin in two strengths, 0.125 mgm and 0.25 mgm. In addition to digoxin, Caraco has received FDA approval for nine generic
drugs over the past six quarters. These are: clozapine, a generic form of Novartis` Clozaril; ticlopidine hydrochloride, a generic form of Hoffman
LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro;
carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s
Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Mr. Borkar said the Company has three additional drugs pending FDA approval and expects to receive approval for these by yearend. He noted that the Company plans to file four new generic-drug applications with the FDA this
year.

Caraco has an extensive R&D Center at its Detroit headquarters complex and receives R&D support from Sun Pharmaceutical Industries Ltd., India`s fifth
largest pharmaceutical firm. Caraco and Sun last year signed a new five-year R&D agreement which calls for the development by Sun of up to 25 new generic
drugs. Sun is a major stockholder of Caraco.


Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to
the nation`s largest wholesalers, distributors, drugstore chains and healthcare systems.

This news release contains forward-looking statements made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Such statements are based on management`s current expectations and are
subject to risk factors and uncertainties which could cause actual results to
differ materially from those described in the forward-looking statements.
These risk factors and uncertainties are contained in the Corporation`s
filings with the Securities and Exchange Commission, available free via EDGAR.
The Company assumes no responsibility to update or clarify forward-looking
statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
-0- 02/03/2003
/CONTACT: Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical
Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial
Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd./

[js200]

@NEONO

Es geht noch weiter

JS200

[MRASTA]

oh, JS war schon wieder schneller, sorry.

Aber diese Meldung kann man gerne zweimal reinstellen, oder ?

cu

[js200]

@MRASTA

Auch hier ???????

JS200

[js200]

3,84 geknackt

JS200

[MRASTA]

klar doch, wer STADA hat muss doch auch CARA haben nicht war ?

LAMP ist Sekt oder Selter aber CARA wird doch meine Rente.

cu

[js200]

Das nenn ich saubere Leistung

Caraco Pharm Labs - OTC BB: CARA

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time

Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
3.95 0.52 (15.16) 3.88 (5) 3.95 (5) 15:59
Day Volume Last Size Open High Low
177,800 500 3.45 3.95 3.39
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
+-++ 203 876 4.1094 N/A
Prev Close VWAP Avg Day Vol
3.43 3.7326 N/A

JS200

[js200]

100 % seit meiner Vorstellung vor 4 Monaten, geht doch , oder ??????

Damit lässt es sich leben, gell

JS200

[fonx]

Sollte mit Lamp auch so laufen,tut es aber nicht!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!Schade!!!!!!!!!!!Fonx

[js200]

Na wer sagt`s denn, von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.950
+0.520 +15.16%


Daily Commentary
BUY

Our system recommends BUY as of today. Previous SELL recommendation was made on 1/27/2003 (7) days ago, when the stock price was 3.340. Since then the stock gained 18.26% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up and is overbought.


The correction is over and the stock is starting a new rally. It is again time for bulls. You may make hefty profits if you buy this stock now and hold it until the next sell signal.: eek: Long-term trend is also bullish.

Candlestick Analysis

Today’s Candlestick Patterns:
White Marubozu

Today a White Marubozu formed. Buyers have controlled the price action from the first trade to the last trade. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 3.950
Previous Close 3.430
Change +0.520
% Change +15.16%
Volume 191,300
Stock Activity
Open 3.450
Day`s High 3.950
Day`s Low 3.450
52 Week High 3.960
52 Week Low 1.750

Stock Price History
3 Month % Change 58.00
6 Month % Change 46.30
12 Month % Change 19.70
Stock Statistics
50 Day Close MA 2.833
200 Day Close MA 2.678
65 Day Volume MA 21,234

JS200

[js200]

02/03/2003 (14:24 ET) Caraco Pharmaceutical Receives FDA Approval for Digoxin - PR Newswire
02/03/2003 (11:21 ET) VOLUME(+): CARA Volume 56% > 20-adsv, Stock +4.66% - Knobias
01/16/2003 (10:21 ET) VOLUME(+): CARA Volume 74% > 20-adsv, Stock +11.96% - Knobias
01/06/2003 (06:53 ET) Research and Markets: Drugs - Generic Value Set - M2 Communications


JS200

[js200]

02/04/2003 (07:54 ET) Caraco Pharmaceutical receives FDA approval for digoxin - Datamonitor
02/03/2003 (14:24 ET) Caraco Pharmaceutical Receives FDA Approval for Digoxin - PR Newswire
02/03/2003 (11:21 ET) VOLUME(+): CARA Volume 56% > 20-adsv, Stock +4.66% - Knobias
01/16/2003 (10:21 ET) VOLUME(+): CARA Volume 74% > 20-adsv, Stock +11.96% - Knobias
01/06/2003 (06:53 ET) Research and Markets: Drugs - Generic Value Set - M2 Communications


JS200

[js200]

Ein schönes Wochenende an alle Investierten

JS200

[js200]

Caraco Pharmaceutical Laboratories Q4 Sales Rise 196%; 12-Month Sales Jump 278%; Net Loss Pared 61%
via COMTEX

February 12, 2003

DETROIT, Feb 12, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd., (OTC Bulletin Board: CARA) posted appreciably higher sales and substantially lower net losses for the fourth quarter ended December 31, 2002 and year 2002, Narendra N. Borkar, Chief Executive Officer, reported today.

Fourth-quarter 2002 results

Q4-2002 sales rose 196% to a record $7,552,115, from $2,549,745 for Q4 2001. The gross profit for the quarter increased 133% to $2,953,515 from $1,267,876 Q4 of 2001. Equally important, the net loss for the quarter was reduced 14% to $535,571, or $(0.03) per fully diluted share, from $625,608, or $(.03) per diluted share, for Q4 2001 despite incurring a non-cash Research & Development (R&D) expense of $1,096,704 in Q4 2002 compared to no such expense in Q4 2001.

Q4-2002 results include a 66% increase in R&D spending to $1,904,043, from $1,145,348 for Q4 2001. As noted, $1,096,704 of total R&D expense reflects non-cash payment of 544,000 Caraco shares to Sun Pharmaceutical Industries Limited (Sun Pharma) for one ANDA product per the Company`s R&D agreement with Sun Pharma. Sun Pharma is India`s fifth largest pharmaceutical firm and owns approximately 49% of Caraco.

12-month 2002 results

Full-year results, which include the restatements for Q2 and Q3 of 2002, were the Company`s best. Sales rose 278% to a record $22,380,964, from $5,922,431 for 2001. Gross profit increased 495% to $10,333,554, from $1,736,372 for 2001. The net loss for 2002 was reduced 61% to $2,256,004, or $(0.10) per fully diluted share, from $5,757,463, or $(0.29) per fully diluted share, for 2001, despite incurring a non-cash R&D expense of $3,887,424, as compared to no such expense in 2001. Total R&D expense for the year rose 135% to $7,236,213, from $3,079,804. As noted, $3,887,424 of total R&D expense reflects non-cash payment of 1,632,000 Caraco shares to Sun Pharma for three ANDA products per the Company`s prior R&D agreement with Sun Pharma.

Mr. Borkar said, `2002 was the Company`s best year. We posted record sales and our first-ever profitable quarter. We launched four new generic drugs, which expanded our product line to 13. We received seven FDA approvals for new generic drugs and filed for applications with the FDA for three other generic drugs. We signed a new 5-year, 25-drug R&D agreement with Sun Pharma Global, which assures us of a steady stream of new generic drugs. Sun Pharma Global is a wholly owned subsidiary of Sun Pharma. We moved closer to renegotiating a restructuring of our mortgage loan with the Economic Development Corporation of the City of Detroit. We completed a $1.6 million plant renovation that added production capacity and improved efficiency. And we enhanced our capital position with the completion of a $1.7 million private placement and a $2.5 million extension to a credit facility.

`The Company is moving in the right direction and we hope to perform better during 2003 through higher expected sales. We plan to launch three or four new generic drugs, bringing our formulary to 16 to 17 drugs by year-end. We also anticipate receiving four to six new generic-drugs from Sun Pharma Global under our new R&D agreement.`

Caraco has received FDA approval for 10 generic drugs over the past six quarters. These are: digoxin, a generic form of Glaxo Wellcome`s Lanoxin; clozapine, a generic form of Novartis`Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers, distributors, drugstore chains and healthcare systems.

This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risk factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These uncertainties and risk factors are contained in the Corporation`s filings with the Securities and Exchange Commission, available via EDGAR. The Company assumes no obligation to update or clarify forward- looking statements.

CARACO PHARMACEUTICAL LABORATORIES, LTD., UNAUDITED STATEMENTS OF OPERATIONS PARTICULARS TWELVE MONTHS ENDED THREE MONTHS ENDED DECEMBER 31 DECEMBER 31 2002 2001 2002 2001 Net Sales 22,380,964 5,922,431 7,552,115 2,549,745 Cost of Goods Sold 12,047,410 4,186,059 4,598,601 1,281,869 Gross Profit 10,333,554 1,736,372 2,953,515 1,267,876 Selling, general & administrative expenses 3,321,051 2,171,860 1,021,420 398,284 R&D cost to affiliate 3,887,424 - 1,096,704 - R&D cost other 3,348,789 3,079,804 807,339 1,145,348 Depreciation 506,656 508,634 158,085 127,159 Operating loss (730,365) (4,023,927) (130,033) (402,914) Interest Interest expense (1,539,075) (1,748,922) (408,176) (224,079) Interest income 13,436 15,385 2,638 1,385 Net interest expense (1,525,639) (1,733,537) (405,538) (222,694) Net loss (2,256,004) (5,757,464) (535,571) (625,608) Net loss per basic and diluted common share (.10) (.29) (.03) (.03)
SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CARA)

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[Neono]

Die news scheinen nicht gut anzukommen





1500 zu 3.49 sold (.71ct/Stück). Danke nochmals für den Tipp!


Neono

[js200]

02/12/2003 (10:06 ET) VOLUME(-): CARA Volume 19% > 20-adsv, Stock -6.13% - Knobias
02/12/2003 (09:00 ET) Caraco Pharmaceutical Laboratories Q4 Sales Rise 196%; 12-Month Sales Jump 278%; Net Loss Pared 61% - PR Newswire
02/12/2003 (08:01 ET) Caraco Pharmaceutical Laboratories Restates Q2- and Q3-2002 Earnings For Noncash Charges - PR Newswire
02/04/2003 (07:54 ET) Caraco Pharmaceutical receives FDA approval for digoxin - Datamonitor
02/03/2003 (14:24 ET) Caraco Pharmaceutical Receives FDA Approval for Digoxin - PR Newswire

JS200

[loss_pro]

@ neono

naja, js hat ja auch nur die halbwegs positiven news gepostet. wie du in #92 siehst gab´s da heute noch mehr, die haben schon zu verunsicherungen geführt. und .5 mio verlust bei über 70 mio MCap ist auch nicht gerade erste sahne.

[js200]

Caraco Pharmaceutical Laboratories Forecasts 2003 Revenues of $35 Million
via COMTEX

February 13, 2003

DETROIT, Feb 13, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) 2003 revenues are expected to jump 56% to $35 million, from 2002`s revenues of $22.4 million, which were up 278% from 2001`s revenues, Narendra N. Borkar, Chief Executive Officer, announced today.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, and healthcare systems.

The Company plans to launch three or four new generic drugs in 2003, bringing its formulary to 16 or 17 drugs by yearend. The Company also plans to submit four to six new generic-drug applications to the FDA in 2003. Caraco currently has three drugs pending FDA approval.

Mr. Borkar said, `The positive outlook for 2003 revenue growth reflects good sales across the entire productline, the introduction of three or four new products, and continued strong sales of new products.`

Caraco has received FDA approval for 10 generic drugs over the past six quarters. These are: digoxin, a generic form of Glaxo Wellcome`s Lanoxin; clozapine, a generic form of Novartis`Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Corporation assumes no responsibility to update forward- looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CARA)

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[js200]

02/13/2003 (10:30 ET) Caraco Pharmaceutical Laboratories Forecasts 2003 Revenues of $35 Million - PR Newswire
02/12/2003 (10:06 ET) VOLUME(-): CARA Volume 19% > 20-adsv, Stock -6.13% - Knobias
02/12/2003 (09:00 ET) Caraco Pharmaceutical Laboratories Q4 Sales Rise 196%; 12-Month Sales Jump 278%; Net Loss Pared 61% - PR Newswire
02/12/2003 (08:01 ET) Caraco Pharmaceutical Laboratories Restates Q2- and Q3-2002 Earnings For Noncash Charges - PR Newswire
02/04/2003 (07:54 ET) Caraco Pharmaceutical receives FDA approval for digoxin - Datamonitor


JS200

[Neono]

loss_pro
Es war mir sicherer zu verkaufen. Heute geht es wieder in die grüne Richtung. Habt noch viel Spass damit!


Neono

[js200]

02/14/2003 (15:38 ET) New 10QSB/A just released for CARA - Edgar
02/14/2003 (15:09 ET) New 10QSB/A just released for CARA - Edgar
02/14/2003 (13:08 ET) New SC 13D/A just released for CARA - Edgar
02/13/2003 (10:30 ET) Caraco Pharmaceutical Laboratories Forecasts 2003 Revenues of $35 Million - PR Newswire
02/12/2003 (10:06 ET) VOLUME(-): CARA Volume 19% > 20-adsv, Stock -6.13% - Knobias


JS200

[js200]

Js200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.650
+0.150 +4.29%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 2/11/2003 (8) days ago, when the stock price was 3.750. Since then the stock fell -2.67% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is normal. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 3.650
Previous Close 3.500
Change +0.150
% Change +4.29%
Volume 23,300
Stock Activity
Open 3.550
Day`s High 3.670
Day`s Low 3.500
52 Week High 3.960
52 Week Low 1.750

Stock Price History
3 Month % Change 46.00
6 Month % Change 33.21
12 Month % Change 14.06
Stock Statistics
50 Day Close MA 3.036
200 Day Close MA 2.701
65 Day Volume MA 26,860

JS200

[js200]

Wird auch immer ruhiger um Cara

9 Generika Fda-zulassungen!!!!!!!!

JS200

[js200]

@ALLE

Von GESTERN : VORSICHT!!!!!!!!!!!!!!!!!!!!!!!!!

CARA
CARACO PHARMACEUTICAL LABS INC
3.270
-0.030 -0.91%


Daily Commentary
SELL

Our system recommends SELL as of today. Previous BUY recommendation was made on 2/24/2003 (3) days ago, when the stock price was 3.560. Since then the stock fell -8.15% .

Today the stock closed lower, at its low (sign of weakness) with a lower high and a lower low. The volume is extremely low. The security price is trending down.


There is a strong downward move that turned down all the moving averages. This may be a sign of a new downtrend. It is still not too late to sell this stock.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 3.270
Previous Close 3.300
Change -0.030
% Change -0.91%
Volume 11,800
Stock Activity
Open 3.300
Day`s High 3.300
Day`s Low 3.270
52 Week High 3.960
52 Week Low 1.750

Stock Price History
3 Month % Change 23.40
6 Month % Change 21.11
12 Month % Change 7.21
Stock Statistics
50 Day Close MA 3.133 DIE DIENT ZUR UNTERSTÜTZUNG
200 Day Close MA 2.719
65 Day Volume MA 27,348

JS200

[js200]

Die GAPunterstützung scheint zu halten

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.110
-0.040 -1.27%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 2/28/2003 (4) days ago, when the stock price was 3.080. Since then the stock gained 0.97% .

Today the stock closed lower, close to its low (sign of weakness) with an unchanged high and a higher low. The volume is extremely low. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 3.110
Previous Close 3.150
Change -0.040
% Change -1.27%
Volume 3,100
Stock Activity
Open 3.150
Day`s High 3.150
Day`s Low 3.100
52 Week High 3.960
52 Week Low 1.750

Stock Price History
3 Month % Change 13.09
6 Month % Change 16.04
12 Month % Change 3.67
Stock Statistics
50 Day Close MA 3.165
200 Day Close MA 2.724
65 Day Volume MA 28,451

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.930
-0.030 -1.01%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 2/28/2003 (11) days ago, when the stock price was 3.080. Since then the stock fell -4.87% .

Today the stock closed lower with a lower high and a lower low. The volume is extremely low. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 2.930
Previous Close 2.960
Change -0.030
% Change -1.01%
Volume 7,500
Stock Activity
Open 2.960
Day`s High 2.960
Day`s Low 2.920
52 Week High 3.960
52 Week Low 1.750

Stock Price History
3 Month % Change 11.83
6 Month % Change 8.52
12 Month % Change -5.48
Stock Statistics
50 Day Close MA 3.215
200 Day Close MA 2.725
65 Day Volume MA 28,972

JS200

[js200]

CARA
CARACO PHARMACEUTICAL LABS INC
2.850
0.000 0.00%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 2/28/2003 (14) days ago, when the stock price was 3.080. Since then the stock fell -7.47% .

Today the stock closed unchanged, at its high (sign of strength) with an unchanged high and a higher low. The volume is low. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
Short White Candlestick

Today a Short White Candlestick formed. There was a limited price change that may represent consolidation.

Stock Quote
Last 2.850
Previous Close 2.850
Change 0.000
% Change 0.00%
Volume 15,800
Stock Activity
Open 2.820
Day`s High 2.850
Day`s Low 2.820
52 Week High 3.960
52 Week Low 1.750

Stock Price History
3 Month % Change 9.62
6 Month % Change 6.34
12 Month % Change -10.94
Stock Statistics
50 Day Close MA 3.227
200 Day Close MA 2.721
65 Day Volume MA 29,248

JS200

[js200]

Auf ein neues

http://www.tradetrek.com/NN/default.asp?symbol=CARA

JS200

[js200]

http://www.tradetrek.com/NN/default.asp?symbol=cara

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.040
+0.130 +4.47%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 3/24/2003 (3) days ago, when the stock price was 2.850. Since then the stock gained 6.67% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a lower low (sign of increase in volatility). The volume is low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Marubozu

Today a White Marubozu formed. Buyers have controlled the price action from the first trade to the last trade. Be careful, this may be a potential turning point!

Stock Quote
Last 3.040
Previous Close 2.910
Change +0.130
% Change +4.47%
Volume 17,200
Stock Activity
Open 2.900
Day`s High 3.040
Day`s Low 2.900
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change 16.92
6 Month % Change 61.70
12 Month % Change -18.93
Stock Statistics
50 Day Close MA 3.263
200 Day Close MA 2.723
65 Day Volume MA 28,706

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.070
+0.030 +0.99%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 3/24/2003 (4) days ago, when the stock price was 2.850. Since then the stock gained 7.72% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is extremely low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 3.070
Previous Close 3.040
Change +0.030
% Change +0.99%
Volume 6,300
Stock Activity
Open 3.010
Day`s High 3.070
Day`s Low 3.010
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change 15.85
6 Month % Change 61.58
12 Month % Change -17.03
Stock Statistics
50 Day Close MA 3.265
200 Day Close MA 2.725
65 Day Volume MA 28,675

JS200

[JS222]

StockDiagnostics.com Upgrades Caraco Pharmaceutical`s OPS Rating
via CDS

April 8, 2003

Caraco Pharmaceutical Laboratories, Ltd. (OTC:CARA) reported positive OPS (Operational-cashflow Per Share) for its quarter ended December 31, 2002 and StockDiagnostics.com has upgraded its OPS Rating to `6`from its previous OPS Rating of `7`. Its OPS Rating has been upgraded for the second consecutive quarter. Caraco Pharmaceutical`s OPS Rating of `6`is its highest over its previous five years.



The OPS RatingTM upgrade was based on Caraco Pharmaceutical`s recently filed Cash Flow Statements for its quarter ended December 31, 2002. The company`s computed OPS TM (Operational-cashflow Per Share) for the quarter was $0.05 per share as compared to $-0.11 per share for the comparable year earlier quarter. OPS for the most recent 12 months ended December 31, 2002 was $-0.04 per share as compared to $-0.33 per share for the 12 months ended December 31, 2001. OPS for Caraco Pharmaceutical`s trailing twelve months reached a six year high.



The shares of Caraco Pharmaceutical were recently trading at $3.02.



About OPS RatingsTM changes -- OPS Rating upgrades and downgrades may predict changes in the momentum of a company`s stock price and its inherent or presumed financial health. All OPS Rating downgrades, even a downgrade from the highest OPS Rating of `1`to the second highest OPS Rating of `2`should be treated with equal caution. Similarly, all OPS Rating upgrades should be considered as equally positive. Even an upgrade from the lowest OPS Rating of `8`to the second lowest OPS Rating of `7`can be treated with guarded optimism.



About OPS RatingsTM -- StockDiagnostics.com monitors a public company`s Operational cash flow Per Share (`OPS`) and assigns it an `OPS Rating`, which measures the long term risk associated with a company`s ability to remain in business. A company`s `OPS`logically falls into a mathematical sequence that ranks it into one of eight distinctive `risk`categories. Each of the categories is based on a company`s operating cash flow for each of its last 4 quarters and its cumulative operating cash flow for its most recent 12 months. OPS Ratings are upgraded, downgraded or reiterated each time a company files a quarterly report and at any time that its financial statements are amended. Statistical research on OPS Ratings is available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.



About StockDiagnostics.com -- StockDiagnostics.com has a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement anomalies and securities pricing variances to monitor changes in the performance of public companies. Go to http://www.StockDiagnostics.com/marketnews for a description of StockDiagnostics.com`s patent-pending technical applications, such as OPS, OPS Ratings, The EPS Syndrome and more. Full details are available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.




Print story

Current Quote

OBB: CARA
Biotech/Medical

Last: 3.000
Change: -0.020
Volume: 18,100
Day High: 3.000
Day Low: 3.000



First Alert News
Get real-time CARA release alerts by entering your email address below.

JS200

[JS222]

http://www.caraco.com/

JS200

[JS222]

News Release
Caraco Pharmaceutical Receives FDA Approval for Digoxin

DETROIT, Feb. 3 -- Caraco Pharmaceutical Laboratories, Ltd., (OTC Bulletin Board: CARA) has received approval from the US Food and Drug Administration (FDA) to manufacture and market digoxin, a generic form of Glaxo Wellcome`s Lanoxin, Narendra N. Borkar, Chief Executive Officer, announced today.
Digoxin is prescribed for the treatment of mild to moderate cardiac failure and has a US market of about $155 million. Caraco will produce digoxin in two strengths, 0.125 mgm and 0.25 mgm.
In addition to digoxin, Caraco has received FDA approval for nine generic drugs over the past six quarters. These are: clozapine, a generic form of Novartis` Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi- Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.
Mr. Borkar said the Company has three additional drugs pending FDA approval and expects to receive approval for these by yearend. He noted that the Company plans to file four new generic-drug applications with the FDA this year.
Caraco has an extensive R&D Center at its Detroit headquarters complex and receives R&D support from Sun Pharmaceutical Industries Ltd., India`s fifth largest pharmaceutical firm. Caraco and Sun last year signed a new five-year R&D agreement which calls for the development by Sun of up to 25 new generic drugs. Sun is a major stockholder of Caraco.
Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers, distributors, drugstore chains and healthcare systems.
This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risk factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These risk factors and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Company assumes no responsibility to update or clarify forward-looking statements.



JS200

[JS222]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.800
-0.200 -6.67%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 4/2/2003 (7) days ago, when the stock price was 3.050. Since then the stock fell -8.20% .

Today the stock closed lower, close to its low (sign of weakness) with a lower high and a lower low. A bearish gap occured, which may indicate a sell off.The volume is high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Black Candlestick

Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.

Stock Quote
Last 2.800
Previous Close 3.000
Change -0.200
% Change -6.67%
Volume 50,100
Stock Activity
Open 2.850
Day`s High 2.970
Day`s Low 2.780
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change 4.09
6 Month % Change 55.56
12 Month % Change -12.50
Stock Statistics
50 Day Close MA 3.210
200 Day Close MA 2.741
65 Day Volume MA 28,765

JS200

[JS222]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.720
-0.080 -2.86%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 4/2/2003 (8) days ago, when the stock price was 3.050. Since then the stock fell -10.82% .

Today the stock closed lower with a lower high and a lower low. The volume is extremely high. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Black Candlestick

Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.

Stock Quote
Last 2.720
Previous Close 2.800
Change -0.080
% Change -2.86%
Volume 89,800
Stock Activity
Open 2.780
Day`s High 2.800
Day`s Low 2.650
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change 1.12
6 Month % Change 47.03
12 Month % Change -11.11
Stock Statistics
50 Day Close MA 3.197
200 Day Close MA 2.742
65 Day Volume MA 29,995

JS200

[JS222]

S-8: CARA Registers 3.2M Shares for Stock Plans

Thursday , April 10, 2003 14:31 ET

Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) filed an S-8 during Thursday’s session.

The Company is registering 3,262,375 shares of common stock issuable under THE 1993 STOCK OPTION PLAN and THE 1999 EQUITY PARTICIPATION PLAN.


JS200

[js200]

Was ist denn bei CARA los, Volumen steigt täglich an ?????????

3:53pm ET
2.60
0.05 (1.96%)
Day`s Range: 2.50 - 2.70
Day`s Volume: 130,600
Avg. Volume: 31,918


JS200

[js200]

04/14/2003 (17:29 ET) New SB-2/A just released for CARA - Edgar
04/10/2003 (14:31 ET) S-8: CARA Registers 3.2M Shares for Stock Plans - Knobias
04/10/2003 (14:23 ET) New S-8 just released for CARA - Edgar
03/31/2003 (15:41 ET) New 10KSB just released for CARA - Edgar

JS200

[js200]

Geht es heute CARA an die Socken ????????

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.600
+0.050 +1.96%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 4/2/2003 (12) days ago, when the stock price was 3.050. Since then the stock fell -14.75% .

Today the stock closed higher with a lower high and a higher low (sign of decrease in volatility). The volume is extremely high. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 2.600
Previous Close 2.550
Change +0.050
% Change +1.96%
Volume 135,700
Stock Activity
Open 2.550
Day`s High 2.700
Day`s Low 2.500
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change -7.14
6 Month % Change 42.08
12 Month % Change -15.58
Stock Statistics
50 Day Close MA 3.164
200 Day Close MA 2.740
65 Day Volume MA 33,560

JS200

[js200]

Von gestern

CARA
CARACO PHARMACEUTICAL LABS INC
2.850
+0.150 +5.56%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 4/2/2003 (14) days ago, when the stock price was 3.050. Since then the stock fell -6.56% .

Today the stock closed higher, at its high (sign of strength) with a higher high and an unchanged low. The volume is extremely low. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
White Marubozu

Today a White Marubozu formed. Buyers have controlled the price action from the first trade to the last trade. Be careful, this may be a potential turning point!

Stock Quote
Last 2.850
Previous Close 2.700
Change +0.150
% Change +5.56%
Volume 16,200
Stock Activity
Open 2.550
Day`s High 2.850
Day`s Low 2.550
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change -15.68
6 Month % Change 56.59
12 Month % Change -6.56
Stock Statistics
50 Day Close MA 3.121
200 Day Close MA 2.738
65 Day Volume MA 33,983

JS200

[js200]

PRE 14A: CARA Vote; Directors; Auth Shares; Auditor

Wednesday, April 23, 2003 17:32 ET

According to a PRE 14A filed Wednesday, Caraco Pharmaceutical Laboratories, Ltd. (OTCBB: CARA) will hold its Annual Meeting of Shareholders on June 2, 2003, at 10:00 a.m., Eastern Daylight Saving Time, at The Hotel St. Regis, Detroit, Michigan 48202, to:

1. Elect three directors for three-year terms expiring in 2006 and upon the election and qualification of their successors.

2. Approval of amendment to Amended and Restated Articles of Incorporation increasing the authorized number of common shares to 50 million and of preferred shares to 15 million.

3. Transact any other business that is properly submitted before the Annual Meeting or any adjournments of the Meeting.

JS200

[morchel]

Hier tut mal ein Chart not!



Die dürften ein besseres Management haben als LAMP

nur die erhöhung der Anzahl der Autorisierten Aktien ist nicht besonders gut, ebenso die lanfristigen Verpflichtungen!

Aber die Shareholder mögen CARA und das ist wichtig!

morchel

[js200]

Caraco Pharmaceutical and Detroit EDC Sign New Mortgage
via COMTEX

April 24, 2003

DETROIT, Apr 24, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd., (OTC Bulletin Board: CARA) has signed a restructured six-year mortgage agreement with the Economic Development Corporation of the City of Detroit, Narendra N. Borkar, Chief Executive Officer, reported today.

Principal terms of the restructured mortgage agreement are considerably more favorable to the Company than the original mortgage, of which the Company was in default. According to the terms of the restructured agreement, the $7.6 million loan to Caraco will carry a graduated interest rate beginning at 2.75% for the first year and increasing to 5.16% for the sixth and final year. In addition, the EDC waived the requirement that Caraco`s inventory and receivables were included as collateral, giving the Company more financial flexibility. The EDC, however, would continue to hold first mortgage of the property and first lien on the plant and equipment and the intellectual property.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz, both of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories (CARA)

Copyright (C) 2003 PR Newswire. All rights reserved.

Print story

Current Quote

OBB: CARA
Biotech/Medical

Last: 3.020
Change: 0.020
Volume: 4,200
Day High: 3.020
Day Low: 3.000



First Alert News
Get real-time CARA release alerts by entering your email address below.

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.030
+0.080 +2.71%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/25/2003 (0) days ago, when the stock price was 3.030. Since then the stock gained 0.00% .

Today the stock closed higher with a higher high and an unchanged low. The volume is normal. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 3.030
Previous Close 2.950
Change +0.080
% Change +2.71%
Volume 27,800
Stock Activity
Open 2.950
Day`s High 3.050
Day`s Low 2.950
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change -9.28
6 Month % Change 15.21
12 Month % Change -9.28
Stock Statistics
50 Day Close MA 3.036
200 Day Close MA 2.740
65 Day Volume MA 32,002

JS200

[js200]

Last Trade: 3.370 Change: 0.320 (+10.492%)
Previous Close: 3.050 Volume: 53,800
Bid: 3.200 Ask: 3.370
Today`s Open: 3.050 # of Trades: 60


Day High: 3.370 Day Low: 3.050
52 Week High: 3.980 52 week Low: 1.720
Market Cap: 80.08M Avg Daily Vol: 36,840
EPS: -0.10 PE Ratio: -33.700
Dividend: N/A Yield: N/A

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.370
+0.320 +10.49%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/25/2003 (4) days ago, when the stock price was 3.030. Since then the stock gained 11.22% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
White Marubozu

Today a White Marubozu formed. Buyers have controlled the price action from the first trade to the last trade. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 3.370
Previous Close 3.050
Change +0.320
% Change +10.49%
Volume 55,500
Stock Activity
Open 3.050
Day`s High 3.370
Day`s Low 3.050
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change -0.88
6 Month % Change 32.16
12 Month % Change 10.49
Stock Statistics
50 Day Close MA 3.032
200 Day Close MA 2.745
65 Day Volume MA 32,318

JS200

[MRASTA]

jep, jetzt geht es durch die Decke, endlich mal auf dasrichtige Pferd gesetzt. Und hüh.


Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million
30 Apr 2003, 10:00am ET
E-mail or Print this story
- - - - -

Q1 Second-Ever Profitable Quarter

DETROIT, April 30 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) posted net income of $2,204,749, or $0.09 per diluted share, on record sales of $8,721,600 for the first quarter of 2003, Narendra N. Borkar, Chief Executive Officer, reported today.

Q1-2003 net sales rose 164% over Q1-2002 net sales of $3,301,959. The Q1- 2003 net sales were up 16% over net sales of $7,552,115 for Q4 2002.

The Q1-2003 gross profit of $4,495,651 was up 209% over Q1-2002`s gross profit of $1,454,412.

The net profit for the quarter was $2,204,749, or $0.09 per diluted share, a 525% turnaround from the year-earlier net loss of $519,241, or $(0.03) per diluted share.

Mr. Borkar said, "The first period of 2003 was our best quarter ever. We generated strong sales for most of the 13 drugs in our formulary and especially robust sales of newer approved products.

"Both gross margin and our bottom-line improved appreciably, reflecting the success of our vertical-integration efforts and the purchase of raw materials and active substances at highly competitive prices. These positive operating results also reflect enhanced manufacturing efficiencies and economies of scale due to larger production-batch sizes.

"We also continued to work closely with Sun Pharmaceutical Industries, most notably in R&D," he said.

The Company has 20 drugs in various stages of development.

Mr. Borkar noted that the Company had restructured it mortgage loan with the Economic Development Corporation of the City of Detroit. The new agreement, which has been under negotiation for several years, provides the Company with considerably more favorable interest rates and terms.

"Looking forward, we are very optimistic about the second quarter and coming year. We are on plan to achieve forecasted 2003 sales of $35 million, which would represent a 56% jump over 2002 sales. We expect our strong sales momentum to continue through the second quarter and the entire year.

"We expect approval, this year, of the three drugs currently under FDA review and we plan to file two or three new FDA drugs applications with the FDA. We also plan to launch three or four generic drugs in 2003, raising our formulary to 16 or 17.

"While we did not incur a R&D technology-transfer charge during the first quarter, we expect, on average, to receive five or six generic drugs (technology transfers) from Sun Pharma/Sun Global each year over a period of five years under our previously announced R&D Agreement. In the absence of an R&D technology-transfer charge, we would expect the second quarter of 2003 to be profitable, as well," he said.

Under terms of its R&D Agreement, Sun Pharma and its subsidiary Sun Global will provide Caraco Pharma with 25 generic drugs over the course of five years. Caraco remits 544,000 shares of a newly issued nonvoting preferred stock for each technology transfer (generic drug) and simultaneously incurs a non-cash charge for the aggregate amount, based on the share price of Caraco`s common stock.

Caraco has received FDA approval for 10 generic drugs over the past eight quarters. These are: digoxin, a generic form of Glaxo Wellcome`s Lanoxin; clozapine, a generic form of Novartis` Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies. Sun Pharmaceutical Industries Ltd., is India`s fifth largest pharmaceutical company and owns about one-half of Caraco`s outstanding shares of common stock.

[MRASTA]

@js

erinnerst Du Dich noch, siehe #82.

Hoffe, Du hast ordentlich zugeschlagen, um die LAMP Wunden zu heilen.

Gruß
mrasta

[morchel]

auf zu alten Höhen würde ich sagen.....

morchel

[MRASTA]

naja, lassen wir die Decke wieder runter kommen.

Hätte ja nun wenigstens gedacht, dass Sie mal Ihr 52 W High erreichen. Beglücke ich mich heute halt mit Portal und Tiny, ist ja auch recht nett.

Egal, noch zwei solche Quartale, dann raus aus der OTC-BB und schon sind die Fonds zur Stelle.

Wenn die Fabrik nicht abbrennt, wüßte ich nicht was man mit Caraco falsch machen sollte.

Schönen Abend allen

mrasta

[js200]

Hätte mit mehr Volumen gerechnet

JS200

[MRASTA]

Volumen war doch nicht so schlecht. Hätte nur erwartet, dass sie mal auf das 52 W High gehen.

Zu Anfang ist es ja recht gut abgegangen, aber wie so viele Firmen im Moment, werden gute Zahlen dazu genutzt um die Aktienmenge zu erhöhen. So auch bei CARAO, die die Menge von 30 auf 50 Mio erhöhen wollen. Siehe Filing 14A von heute.

Das erklärt dann auch den Kursverlauf von heute. Ärgerlich, ja, keine Frage, habe langsam die Schnauze gestrichen voll, nicht von CARACO, ganz und gar nicht, aber es hat sich im Moment so eingebürgert, dass alle Firmen Ihre Aktienzahlen erhöhen und das frustet einfach.

Auf Grund der guten Zahlen wurde dieses heute noch ganz gut abgefedert, mal sehen was die nächsten Tage bringen, da die Info nachbörslich rauskam. Wußten wohl schon wieder einige mehr als wir.

Bin trotzdem der Meinung, das CARACO uns noch viel Freude bereiten wird. Allerdings ist zu befürchten, dass es erst mal wieder gen Süden geht.

Gruß
mrasta

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
3.450
+0.080 +2.37%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/25/2003 (5) days ago, when the stock price was 3.030. Since then the stock gained 13.86% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 3.450
Previous Close 3.370
Change +0.080
% Change +2.37%
Volume 170,100
Stock Activity
Open 3.400
Day`s High 3.750
Day`s Low 3.350
52 Week High 3.950
52 Week Low 1.750

Stock Price History
3 Month % Change 2.37
6 Month % Change 37.45
12 Month % Change 15.00
Stock Statistics
50 Day Close MA 3.031
200 Day Close MA 2.748
65 Day Volume MA 34,515

JS200

[js200]

04/30/2003 (17:01 ET) New DEF 14A just released for CARA - Edgar
04/30/2003 (10:00 ET) Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million - PR Newswire
04/24/2003 (10:00 ET) Caraco Pharmaceutical and Detroit EDC Sign New Mortgage - PR Newswire
04/23/2003 (17:32 ET) PRE 14A: CARA Vote; Directors; Auth Shares; Auditor - Knobias
04/23/2003 (17:25 ET) New PRE 14A just released for CARA - Edgar


JS200

[js200]

@MRASTA

Aktienmengenerhöhung ist nicht unbedingt sicher, dass diese Teile sofort auf den Markt kommen, könnten auch genutzt werden für Einkäufe usw.

JS200

[js200]

Lauf weiter, so ist es recht

JS200

[js200]

05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar
05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar
05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar
04/30/2003 (17:01 ET) New DEF 14A just released for CARA - Edgar
04/30/2003 (10:00 ET) Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million - PR Newswire


JS200

[MRASTA]

@js

Ist dass jetzt ein Fonds Alarm ?

Zumindest haste Dein Volumen und ich auch.

mrasta

[js200]

@MRASTA

Volumen über 300.000 ist schon sehr viel für CARA

könnte sein

JS200

[js200]

@MRASTA

Schafft CARA den Bruch durch die 4 Dollar ???????

Last Trade: 3.960 Change: 0.210 (+5.600%)
Previous Close: 3.750 Volume: 71,400
Bid: 3.950 Ask: 3.960
Today`s Open: 3.700 # of Trades: 55

JS200

[MRASTA]

@js

klar doch.

Gerade bei 4.00 $ angekommen.

[js200]

05/06/2003 (14:25 ET) New 8-K just released for CARA - Edgar
05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar
05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar
05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar
04/30/2003 (17:01 ET) New DEF 14A just released for CARA - Edgar

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
4.010
+0.260 +6.93%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/25/2003 (11) days ago, when the stock price was 3.030. Since then the stock gained 32.34% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 4.010
Previous Close 3.750
Change +0.260
% Change +6.93%
Volume 191,800
Stock Activity
Open 3.700
Day`s High 4.020
Day`s Low 3.700
52 Week High 4.010
52 Week Low 1.750

Stock Price History
3 Month % Change 9.56
6 Month % Change 60.40
12 Month % Change 33.67
Stock Statistics
50 Day Close MA 3.036
200 Day Close MA 2.765
65 Day Volume MA 42,882

JS200

[MRASTA]

@js

ups, wo soll dass denn enden.

Mist, wollte eigentlich noch nachlegen. Warte aber erstmal bis die Kaufwüttigen fertig haben, hoffe auf einen kleinen Rücksetzer.

Wie siehst Du das ?

Hast mal den Q-Bericht genauer durchgelesen, ist interessant, dann weiß Du auch wozu die neuen Teile gebraucht werden, sehr clever.

mrasta

[morchel]

Phantastisch



morchel

[js200]

@MRASTA

Nein, ich weiss nicht wofür, dass die neuen Teile benutzt werden.

Habe auch nur 1.000 Teile zu 2,22 Dollar, leider

JS200

[js200]

52W HIGH: New 52-Wk High for CARA @ $4.030 up0.50%

Wednesday, May 07, 2003 10:06 ET

This is the 1st 52 WEEK HIGH alert for CARA in the past 7 calendar days.

The share price for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) reached a new 52-week high today, trading at $4.030, up $0.020 (0.50%) from its previous close of $4.010.

The Company`s previous 52-week high of $4.020 was set yesterday on May 06, 2003.

One year ago, the Company`s shares closed at $3.000. The price has climbed more than 34 percent since then.

At the time of this alert, the stock had traded 17,400 shares via 14 trades, 77.02% below it`s 20day average of 75,715 shares.

This new 52-week high currently puts the stock:

30.84% above its 20day Moving Average of $3.080
32.73% above its 50day Moving Average of $3.036
31.56% above its 100day Moving Average of $3.063

The Company last released news on April 30, 2003:

"Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million"

CARACO PHARMACEUTICAL LABS LTD
Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes nine products in 14 strengths in 33 package sizes. In 2001 the Company`s product portfolio included 12 products in 22 strengths in 36 package sizes. The Company markets all 12 products, and the Company`s drugs relate to a variety of therapeutic segments including the central nervous system, cardiology, pain management and diabetes.

JS200

[js200]

@MRASTA

Kommt dir das nicht bekannt vor :

CARACO PHARMACEUTICAL LABS LTD
Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes nine products in 14 strengths in 33 package sizes. In 2001 the Company`s product portfolio included 12 products in 22 strengths in 36 package sizes. The Company markets all 12 products, and the Company`s drugs relate to a variety of therapeutic segments including the central nervous system, cardiology, pain management and diabetes.


JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


05/07/2003 (10:57 ET) VOLUME(+): CARA Volume 17% > 20-adsv, Stock +7.98% - Knobias



05/07/2003 (10:06 ET) 52W HIGH: New 52-Wk High for CARA @ $4.030 up0.50% - Knobias



05/06/2003 (14:25 ET) New 8-K just released for CARA - Edgar



05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar



05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar



05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar



04/30/2003 (17:01 ET) New DEF 14A just released for CARA - Edgar



04/30/2003 (10:00 ET) Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million - PR Newswire



04/24/2003 (10:00 ET) Caraco Pharmaceutical and Detroit EDC Sign New Mortgage - PR Newswire



04/23/2003 (17:32 ET) PRE 14A: CARA Vote; Directors; Auth Shares; Auditor - Knobias



04/23/2003 (17:25 ET) New PRE 14A just released for CARA - Edgar



04/14/2003 (17:29 ET) New SB-2/A just released for CARA - Edgar



04/10/2003 (14:31 ET) S-8: CARA Registers 3.2M Shares for Stock Plans - Knobias



04/10/2003 (14:23 ET) New S-8 just released for CARA - Edgar


JS200

[MRASTA]

@js

lange darüber nachgedacht. Dass eine kann es nicht sein, bzw. dauert noch ewig, bleibt nur die andere Möglichkeit.

Wäre schon was. Hast Du infos oder nur so ?



Mal sehen ob die 4.00 bei CARA halten, Ansturm ist wohl erstmal vorbei, gibt wohl erstmal einen Rücksetzer.

mrasta

[js200]

3:59pm ET
4.25
0.05 (1.19%)
Day`s Range: 4.21 - 4.65
Day`s Volume: 109,800
Avg. Volume: 0


JS200

[js200]

Last Trade: 4.360 Change: 0.120 (+2.830%)
Previous Close: 4.240 Volume: 53,900
Bid: 4.300 Ask: 4.360
Today`s Open: 4.230 # of Trades: 52

JS200

[js200]

Performance (%-changes)
1 week: +14.66%
1 month: +68.62%
1 year: +53.57%


Lässt sich doch sehen, oder was meint Ihr

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
4.300
+0.060 +1.42%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/25/2003 (17) days ago, when the stock price was 3.030. Since then the stock gained 41.91% .

Today the stock closed higher with a higher high and a lower low (sign of increase in volatility). The volume is high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 4.300
Previous Close 4.240
Change +0.060
% Change +1.42%
Volume 72,900
Stock Activity
Open 4.230
Day`s High 4.360
Day`s Low 4.170
52 Week High 4.300
52 Week Low 1.750

Stock Price History
3 Month % Change 22.51
6 Month % Change 83.76
12 Month % Change 78.79
Stock Statistics
50 Day Close MA 3.114
200 Day Close MA 2.794
65 Day Volume MA 47,922

JS200

[js200]

Last Trade: 4.520 Change: 0.220 (+5.116%)
Previous Close: 4.300 Volume: 45,100
Bid: 4.500 Ask: 4.550
Today`s Open: 4.350 # of Trades: 51


Läuft von Tag zu Tag immer besser

JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
4.450
-0.070 -1.55%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/25/2003 (19) days ago, when the stock price was 3.030. Since then the stock gained 46.86% .

Today the stock closed lower with an unchanged high and a higher low. The volume is low. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Black Candlestick

Today a Black Candlestick formed. Sellers were in control but the selling pressure was not very strong.

Stock Quote
Last 4.450
Previous Close 4.520
Change -0.070
% Change -1.55%
Volume 26,500
Stock Activity
Open 4.550
Day`s High 4.550
Day`s Low 4.400
52 Week High 4.520
52 Week Low 1.750

Stock Price History
3 Month % Change 34.85
6 Month % Change 90.99
12 Month % Change 68.56
Stock Statistics
50 Day Close MA 3.168
200 Day Close MA 2.812
65 Day Volume MA 48,322

JS200

[js200]

05/15/2003 (14:37 ET) New 10QSB just released for CARA - Edgar
05/07/2003 (10:57 ET) VOLUME(+): CARA Volume 17% > 20-adsv, Stock +7.98% - Knobias
05/07/2003 (10:06 ET) 52W HIGH: New 52-Wk High for CARA @ $4.030 up0.50% - Knobias
05/06/2003 (14:25 ET) New 8-K just released for CARA - Edgar
05/02/2003 (08:14 ET) New 4 just released for CARA - Edgar

JS200

[js200]

http://knobias.10kwizard.com/contents.php?ipage=2155574&repo…

JS200

[js200]

Net income / (loss) per basic and diluted common share 0.09

JS200

[js200]

PRE 14A: CARA Vote; Directors; Auth Shares; Auditor

Monday , June 02, 2003 07:02 ET

Caraco Pharmaceutical Laboratories, Ltd. (OTCBB: CARA) will hold its Annual Meeting of Shareholders on June 2, 2003, at 10:00 a.m., Eastern Daylight Saving Time, at The Hotel St. Regis, Detroit, Michigan 48202, to:

1. Elect three directors for three-year terms expiring in 2006 and upon the election and qualification of their successors.

2. Approval of amendment to Amended and Restated Articles of Incorporation increasing the authorized number of common shares to 50 million and of preferred shares to 15 million.

3. Transact any other business that is properly submitted before the Annual Meeting or any adjournments of the Meeting.



Misc Releated Info:
** Original Confirmation

JS200

[MRASTA]

Sie steigt und steigt und steigt, zwar langsam aber stetig.

Und jetzt erst recht :


12.06.2003 - 19:57 Uhr
US/Bush weist FDA zu beschleunigter Generika-Genehmigung an

Washington (vwd) - US-Präsident George W. Bush hat die US-Gesundheitsbehörde FDA angewiesen, künftig die Genehmigung von generischen Medikamenten zu beschleunigen. Als einen ersten Schritt solle die FDA den Pharmaunternehmen bei einem Medikament, das seinen Patentschutz verliert, nur eine einmalige Frist von 30 Monaten einräumen, bevor ein Nachahmerproduzent sein Produkt auf den Markt bringen kann, sagte Bush in einer Rede am Donnerstag. Pharmaunternehmen solle es auch untersagt werden, ihre Patente nur aufgrund von geringfügigen Innovationen zu verlängern.
vwd/DJ/12.6.2003/apo/mi

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/12/2003 (14:16 ET) VOLUME(+): CARA Volume 54% > 20-adsv, Stock +10.34% - Knobias



06/12/2003 (11:06 ET) 52W HIGH: New 52-Wk High for CARA @ $4.700 up8.05% - Knobias



06/11/2003 (15:22 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +8.59% - Knobias



06/02/2003 (07:02 ET) PRE 14A: CARA Vote; Directors; Auth Shares; Auditor - Knobias



05/28/2003 (16:16 ET) New SB-2/A just released for CARA - Edgar

JS200

[js200]

VOLUME(+): CARA Volume 54% > 20-adsv, Stock +10.34%

Thursday , June 12, 2003 14:16 ET

This is the 1st VOLUME alert for CARA in the past 7 calendar days.

Trading for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) has been heavier than usual in today`s session. By 14:15 ET, the stock had already traded 75,400 shares via 74 trades. The cumulative volume is 54.03% above its 20-day average of 48,950. Normally the stock experiences around 40 individual trades per session.

So far, today`s volume surge has caused a net rise in CARA`s stock price. At the time of this alert, the stock was trading at $4.800, up $0.450 (+10.34%).

One year ago, the Company`s shares closed at $2.710. The price has gained more than 77 percent since then.

Over the last 10 trading session CARA has traded in a range between $3.810 and $4.600 and is currently trading 3.23% above its 52-week high of $4.650 set on May 07, 2003 and 179.07% above its 52-week low of $1.720 from October 07, 2002.

In the previous 3 sessions, CARA trading has displayed a mixed trend. Closing results have been as follows:

June 11, 2003 --- closed at $4.350 up $0.390 (+9.85%) on 136,700 shares
June 10, 2003 --- closed at $3.960 up $0.060 (+1.54%) on 24,900 shares
June 09, 2003 --- closed at $3.900 down $0.050 (-1.27%) on 18,600 shares

The Company last released news on April 30, 2003:

"Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million"

CARACO PHARMACEUTICAL LABS LTD
Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes nine products in 14 strengths in 33 package sizes. In 2001 the Company`s product portfolio included 12 products in 22 strengths in 36 package sizes. The Company markets all 12 products, and the Company`s drugs relate to a variety of therapeutic segments including the central nervous system, cardiology, pain management and diabetes.

JS200

[MRASTA]

jep, so geht es.


52W HIGH: New 52-Wk High for CARA @ $5.000 up0.40%

This is the 2nd 52 WEEK HIGH alert for CARA in the past 7 calendar days.

The share price for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) reached a new 52-week high today, trading at $5.000, up $0.020 (0.40%) from its previous close of $4.980.

The Company`s previous 52-week high of $4.980 was set 3 days ago on June 13, 2003.

One year ago, the Company`s shares closed at $2.640. The price has climbed more than 89 percent since then.

At the time of this alert, the stock had traded 11,300 shares via 8 trades, 79.41% below it`s 20day average of 54,880 shares.

This new 52-week high currently puts the stock:

18.74% above its 20day Moving Average of $4.211

34.94% above its 50day Moving Average of $3.705

43.91% above its 100day Moving Average of $3.474

The Company last released news on April 30, 2003:

"Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million"

CARACO PHARMACEUTICAL LABS LTD

[morchel]

Ich liebe CARA

Der Grund ist dieser chart:



Das Glück ist ins Hause morchel zurückgekehrt

morchel

[js200]

@MORCHEL

Hatte doch nicht zuviel versprochen beim Vorschlag von CARA

JS200

[js200]

VOLUME(+): CARA Volume 22% > 20-adsv, Stock +8.43%

Monday , June 16, 2003 10:48 ET

This is the 1st VOLUME alert for CARA in the past 7 calendar days.

Trading for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) has been heavier than usual in today`s session. By 10:45 ET, the stock had already traded 67,000 shares via 58 trades. The cumulative volume is 22.08% above its 20-day average of 54,880. Normally the stock experiences around 45 individual trades per session.

So far, today`s volume surge has caused a net rise in CARA`s stock price. At the time of this alert, the stock was trading at $5.400, up $0.420 (+8.43%).

One year ago, the Company`s shares closed at $2.640. The price has gained more than 104 percent since then.

Over the last 10 trading session CARA has traded in a range between $3.810 and $4.980 and is currently trading 8.43% above its 52-week high of $4.980 set on June 13, 2003 and 213.95% above its 52-week low of $1.720 from October 07, 2002.

In the previous 3 sessions, CARA trading has displayed a positive trend. Closing results have been as follows:

June 13, 2003 --- closed at $4.980 up $0.080 (+1.63%) on 66,600 shares
June 12, 2003 --- closed at $4.900 up $0.550 (+12.64%) on 106,900 shares
June 11, 2003 --- closed at $4.350 up $0.390 (+9.85%) on 136,700 shares

The Company last released news on April 30, 2003:

"Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million"

CARACO PHARMACEUTICAL LABS LTD
Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes nine products in 14 strengths in 33 package sizes. In 2001 the Company`s product portfolio included 12 products in 22 strengths in 36 package sizes. The Company markets all 12 products, and the Company`s drugs relate to a variety of therapeutic segments including the central nervous system, cardiology, pain management and diabetes.

JS200

[js200]

@LOSS_PRO

Tradename Generic Ingredient Developers Indications Current Phase Last Modified
Subscription only Subscription only Subscription only Subscription only Subscription only Subscription only 5/5/2003
Levoxyl levothyroxine sodium LEVOTHYROXINE
King Pharmaceuticals
Hypothyroidism
Market 4/29/2003
Unithroid levothyroxine sodium LEVOTHYROXINE
Jerome Stevens Pharmaceuticals
Hypothyroidism
Market 4/23/2003
Photofrin porfimer sodium none Axcan Pharma
Lung cancer
Market 3/20/2003
LAM IPM Wound Gel 2.5% sodium hyaluronate gel none LAM Pharmaceutical Corporation
Wound/ulcer healing
Market 3/6/2003
Sodium Iodide I-131 sodium iodide I-131 none Bracco Diagnostics Inc.
DRAXIMAGE Inc.
DRAXIS Health, Inc.
Hyperparathyroidism
Thyroid cancer
Market 1/29/2003


http://www.biospace.com/ccis/search.cfm?Product=sodium&SR=21

JS200

[js200]

@LOSS_PRO

http://www.biospace.com/ccis/search.cfm?Product=2.5%25%20sod…

JS200

[js200]

06/17/2003 (10:50 ET) VOLUME(+): CARA Volume 15% > 20-adsv, Stock +0.93% - Knobias
06/17/2003 (10:48 ET) 52W HIGH: New 52-Wk High for CARA @ $5.600 up4.67% - Knobias
06/17/2003 (08:12 ET) New SB-2/A just released for CARA - Edgar
06/16/2003 (10:48 ET) VOLUME(+): CARA Volume 22% > 20-adsv, Stock +8.43% - Knobias
06/16/2003 (09:52 ET) 52W HIGH: New 52-Wk High for CARA @ $5.000 up0.40% - Knobias

JS200

[MRASTA]

meine Rente macht sich.

52W HIGH: New 52-Wk High for CARA @ $5.680 up2.33%
Tuesday , June 24, 2003 09:46 ET

This is the 2nd 52 WEEK HIGH alert for CARA in the past 7 calendar days.

The share price for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) reached a new 52-week high today, trading at $5.680, up $0.129 (2.33%) from its previous close of $5.551.

The Company`s previous 52-week high of $5.600 was set 7 days ago on June 17, 2003.

One year ago, the Company`s shares closed at $2.510. The price has climbed more than 126 percent since then.

At the time of this alert, the stock had traded 1,900 shares via 2 trades, 97.07% below it`s 20day average of 64,845 shares.

This new 52-week high currently puts the stock:

24.64% above its 20day Moving Average of $4.557
42.46% above its 50day Moving Average of $3.987
58.14% above its 100day Moving Average of $3.592

The Company last released news on April 30, 2003:

"Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million"

[js200]

@MRASTA

NICHT NUR DEINE

06/25/2003 (11:36 ET) 52W HIGH: New 52-Wk High for CARA @ $5.950 up0.85% - Knobias
06/24/2003 (09:46 ET) 52W HIGH: New 52-Wk High for CARA @ $5.680 up2.33% - Knobias
06/19/2003 (14:11 ET) VOLUME(o): CARA Volume 42% > 20-adsv, Stock EVEN - Knobias
06/17/2003 (10:50 ET) VOLUME(+): CARA Volume 15% > 20-adsv, Stock +0.93% - Knobias
06/17/2003 (10:48 ET) 52W HIGH: New 52-Wk High for CARA @ $5.600 up4.67% - Knobias

JS200

[morchel]

CARA Darling! I kiss you!



morchel

[morchel]

wieder ein neues 52 Wochen hoch!



morchel

[morchel]

CARA bei 7!

morchel

[js200]

07/01/2003 (15:36 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +7.10% - Knobias
07/01/2003 (09:48 ET) 52W HIGH: New 52-Wk High for CARA @ $6.650 up0.45% - Knobias
06/30/2003 (15:41 ET) 52W HIGH: New 52-Wk High for CARA @ $6.570 up1.86% - Knobias
06/27/2003 (11:16 ET) 52W HIGH: New 52-Wk High for CARA @ $6.250 up3.31% - Knobias
06/25/2003 (11:36 ET) 52W HIGH: New 52-Wk High for CARA @ $5.950 up0.85% - Knobias


JS200

[js200]

War doch nicht so übel, 350 % innerhalb 8 Monaten

JS200

[js200]

.
Man bedenke : Dezember 2000 noch bei 0,20 Dollar !!!!!!!!!!!!!!!

Entspricht über 3.000 % innerhalb 30 Monate

Lassen wir sie einfach laufen

JS200

[morchel]

Dieser Chart untermahlt eindrucksvoll den Werdegang von CARA!

Ich habe sie damals ca. Zeitgleich mit LAMP entdeckt und gekauft.

Fazit:

CARA TOP
LAMP FLOP (bisher)



morchel

[MRASTA]

@morchel

zu Deinem Kommtentar fällt mir fast nichts oder auch vieles ein. Glaube aber es ist besser, wenn ich meinen nochmal überdenke.

Wollte nur mal daran erinnern, dass JS den Thread eröffnet hat und Du erst seit dem 24.04.03. hier aktiv bist.

Den Rest spare ich mir lieber.

mrasta

[morchel]

MRASTA, soll ich es dir raussuchen?

morchel

[js200]

52W HIGH: New 52-Wk High for CARA @ $7.200 up11.11%

Thursday , July 03, 2003 12:56 ET

This is the 4th 52 WEEK HIGH alert for CARA in the past 7 calendar days.

The share price for Caraco Pharmaceutical Labs Ltd (OTCBB: CARA) reached a new 52-week high today, trading at $7.200, up $0.720 (11.11%) from its previous close of $6.480.

The Company`s previous 52-week high of $7.120 was set 2 days ago on July 01, 2003.

One year ago, the Company`s shares closed at $2.900. The price has climbed more than 148 percent since then.

At the time of this alert, the stock had traded 152,400 shares via 84 trades, 79.05% above it`s 20day average of 85,115 shares.

This new 52-week high currently puts the stock:

35.49% above its 20day Moving Average of $5.314
60.39% above its 50day Moving Average of $4.489
90.34% above its 100day Moving Average of $3.783

The Company last released news on April 30, 2003:

"Caraco Pharmaceutical Posts Net Income of $2.2 Million on Q1 Net Sales of $8.7 Million"

CARACO PHARMACEUTICAL LABS LTD
Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes nine products in 14 strengths in 33 package sizes. In 2001 the Company`s product portfolio included 12 products in 22 strengths in 36 package sizes. The Company markets all 12 products, and the Company`s drugs relate to a variety of therapeutic segments including the central nervous system, cardiology, pain management and diabetes.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/03/2003 (12:56 ET) 52W HIGH: New 52-Wk High for CARA @ $7.200 up11.11% - Knobias



07/03/2003 (11:51 ET) VOLUME(+): CARA Volume 29% > 20-adsv, Stock +8.02% - Knobias



07/01/2003 (15:36 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +7.10% - Knobias



07/01/2003 (09:48 ET) 52W HIGH: New 52-Wk High for CARA @ $6.650 up0.45% - Knobias



06/30/2003 (15:41 ET) 52W HIGH: New 52-Wk High for CARA @ $6.570 up1.86% - Knobias



06/27/2003 (11:16 ET) 52W HIGH: New 52-Wk High for CARA @ $6.250 up3.31% - Knobias



06/25/2003 (11:36 ET) 52W HIGH: New 52-Wk High for CARA @ $5.950 up0.85% - Knobias



06/24/2003 (09:46 ET) 52W HIGH: New 52-Wk High for CARA @ $5.680 up2.33% - Knobias



06/19/2003 (14:11 ET) VOLUME(o): CARA Volume 42% > 20-adsv, Stock EVEN - Knobias



06/17/2003 (10:50 ET) VOLUME(+): CARA Volume 15% > 20-adsv, Stock +0.93% - Knobias



06/17/2003 (10:48 ET) 52W HIGH: New 52-Wk High for CARA @ $5.600 up4.67% - Knobias



06/17/2003 (08:12 ET) New SB-2/A just released for CARA - Edgar



06/16/2003 (10:48 ET) VOLUME(+): CARA Volume 22% > 20-adsv, Stock +8.43% - Knobias



06/16/2003 (09:52 ET) 52W HIGH: New 52-Wk High for CARA @ $5.000 up0.40% - Knobias



06/12/2003 (14:16 ET) VOLUME(+): CARA Volume 54% > 20-adsv, Stock +10.34% - Knobias



06/12/2003 (11:06 ET) 52W HIGH: New 52-Wk High for CARA @ $4.700 up8.05% - Knobias



06/11/2003 (15:22 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +8.59% - Knobias


JS200

[js200]

@MORCHEL

Hmmmmmmmmmmmmmm

Alle Threadtitel (Seitenansicht) Postings Ansicht Autor Letzte Antwort
CARA**Caraco Pharmaceuticals steigt wieder, der neue PLAYER??? 182 js200 06.07.03 13:09:25
CARA , Supergewinner mit generischen Medikamenten! 4 morchel 30.05.03 01:36:44
Karl (CARAT Global One): "Umschichtung in defensive Anlagen" 1 Redaktion WO [W:O] 08.04.03 21:00:14
Carat Fonds Service AG setzt neues Fondsmanagementkonzept um 1 TeletraderNews [W:O] 12.02.03 17:00:06
Carramba!!! Caracho!!! Spanien : Deutschland 5:0 6 verin 11.02.03 10:25:36
Carat Trading Protect-Konzept für Carat-Stern-Universal 1 Redaktion WO [W:O] 05.02.03 18:00:16
Carat schlägt den Dax mit neuer Strategie 1 DerFonds [W:O] 03.02.03 16:50:06
Carat setzt auf Metzler-Fonds 1 DerFonds [W:O] 05.12.02 11:22:04
CARA wieder auf dem Weg nach oben ???? 1 js200 30.09.02 17:08:45
Premium-Partner Carat und Merrill Lynch 1 Redaktion WO [W:O] 20.08.02 20:54:28
CARACO PHARMACEUTICAL 330 % gestiegen in 30 Tagen 7 js200 22.07.02 23:46:27
Carat Asset setzt `in der jetzigen Kundenverfassung` auf defensive Werte 1 dpaAFX 23.08.01 13:35:05
Carat Asset Management geht an den Start 1 dpaAFX 23.08.01 13:35:02
flugticket von caracas nach deutschland 2 www.hardy.at 04.04.01 21:18:42
«Reise/Camping 2001»: Caravan-Branche zeigt mobile Urlaubsheime 1 ADX 19.03.01 15:24:40
2x Opel ASTRA CARAVAN 09/99 26.500 KM für schlappe DM 22.500.- 1 jaccomoI 16.08.00 13:09:15
eff-eff verkauft Bereich Alarmsysteme an CARADON 1 Redaktion WO [W:O] 06.03.00 08:40:02
AN CARAT 1 zappercop 20.02.00 13:35:41
carat - verschon uns mit deiner Crashhystherie 1 unreal2 29.09.99 08:41:41

JS200

[morchel]

js

kein neuer thread seinerzeit durch mich. Ich erwähnte CARA ein paar mal im Vergleich mit LAMP.

CARA hatte den ersten steilen Kursanstieg nach der FDA Zulassung des ersten Medikamentes und ich erwartete das selbe auch für LAMP!

Hätten die Insider bei LAMP ihre Aktien nicht gedumpt stünde LAMP heute noch um 1!

Bei Bedarf kann ich es aus den alten threads raussuchen.

Aber ich glaube es ist wichtiger das ein paar Leute mit CARA Kohle machen als wer sie gefunden hat!

CARA ist durch sein Geschäftsfeld gut für weiteren Kursgewinn.

Ich erwarte einen Wechsel von CARA bald an AMEX oder NASDAQ(SC)

Jede Krankenversicherung muß sparen darum sind alle Werte die mit Generikern ihr Geld verdienen sehr empfehlenswert!

morchel

[js200]

@MORCHEL

es ist egal, wer was findet, Hauptsache Gewinne winken

Cara, tendiere eher Richtung AMEX

JS200

[morchel]

glaube auch eher AMEX!

morchel

[js200]

CARA - CARACO PHARMACEUTICAL LABS LTD Company Profile

Last
Sale:
-
Best
Bid:
7.2
Best Bid
Depth:
2000
Best
Ask:
7.35
Best Ask
Depth:
1000

MPID Bid Size Ask Size U O/C
FAHN 7.2 500 7.35 500 O
MHMY 6 500 7.35 500 O
HILL 7 500 7.4 500 O
MOKE 7 500 7.4 500 O
NITE 6.95 500 7.4 500 O
WIEN 6.4 500 7.4 500 O
FASI 6.15 500 7.45 500 O
BPAT 6.2 500 7.49 500 O
SCHB 7.2 500 7.5 500 O
TDCM 7.05 500 7.5 500 O
BAMM 6.45 500 7.5 500 O
PERT 7.2 500 7.53 500 O


JS200

[morchel]

CARA 7,8!!!!!

Durchmarsch bis 10?

ähnlich Medifast?

morchel

[morchel]

8 bezahlt

warum hab ich vollhirn nicht mehr gkauft!

morchel

[js200]

@MORCHEL

Mein Ziel ist 8,50, dann bin ich raus, bei 2,2 rein, das reicht

JS200

[js200]

07/07/2003 (12:12 ET) VOLUME(+): CARA Volume 24% > 20-adsv, Stock +5.44% - Knobias
07/07/2003 (10:04 ET) 52W HIGH: New 52-Wk High for CARA @ $7.450 up1.36% - Knobias
07/03/2003 (12:56 ET) 52W HIGH: New 52-Wk High for CARA @ $7.200 up11.11% - Knobias
07/03/2003 (11:51 ET) VOLUME(+): CARA Volume 29% > 20-adsv, Stock +8.02% - Knobias
07/01/2003 (15:36 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +7.10% - Knobias

Last Trade: 8.030 Change: 0.680 (+9.252%)
Previous Close: 7.350 Volume: 337,900
Bid: 8.000 Ask: 8.030
Today`s Open: 7.300 # of Trades: 251

Day High: 8.050 Day Low: 7.250
52 Week High: 7.400 52 week Low: 1.720
Market Cap: 191.18M Avg Daily Vol: 91,855
EPS: -0.10 PE Ratio: -80.300
Dividend: N/A Yield: N/A



!!!!!!!!!!!!!!!!!!!!!!TOTAL ÜBERVERKAUFT!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Rückschlag abwarten

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/07/2003 (12:12 ET) VOLUME(+): CARA Volume 24% > 20-adsv, Stock +5.44% - Knobias



07/07/2003 (10:04 ET) 52W HIGH: New 52-Wk High for CARA @ $7.450 up1.36% - Knobias



07/03/2003 (12:56 ET) 52W HIGH: New 52-Wk High for CARA @ $7.200 up11.11% - Knobias



07/03/2003 (11:51 ET) VOLUME(+): CARA Volume 29% > 20-adsv, Stock +8.02% - Knobias



07/01/2003 (15:36 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +7.10% - Knobias



07/01/2003 (09:48 ET) 52W HIGH: New 52-Wk High for CARA @ $6.650 up0.45% - Knobias



06/30/2003 (15:41 ET) 52W HIGH: New 52-Wk High for CARA @ $6.570 up1.86% - Knobias



06/27/2003 (11:16 ET) 52W HIGH: New 52-Wk High for CARA @ $6.250 up3.31% - Knobias



06/25/2003 (11:36 ET) 52W HIGH: New 52-Wk High for CARA @ $5.950 up0.85% - Knobias



06/24/2003 (09:46 ET) 52W HIGH: New 52-Wk High for CARA @ $5.680 up2.33% - Knobias



06/19/2003 (14:11 ET) VOLUME(o): CARA Volume 42% > 20-adsv, Stock EVEN - Knobias



06/17/2003 (10:50 ET) VOLUME(+): CARA Volume 15% > 20-adsv, Stock +0.93% - Knobias



06/17/2003 (10:48 ET) 52W HIGH: New 52-Wk High for CARA @ $5.600 up4.67% - Knobias



06/17/2003 (08:12 ET) New SB-2/A just released for CARA - Edgar



06/16/2003 (10:48 ET) VOLUME(+): CARA Volume 22% > 20-adsv, Stock +8.43% - Knobias



06/16/2003 (09:52 ET) 52W HIGH: New 52-Wk High for CARA @ $5.000 up0.40% - Knobias



06/12/2003 (14:16 ET) VOLUME(+): CARA Volume 54% > 20-adsv, Stock +10.34% - Knobias



06/12/2003 (11:06 ET) 52W HIGH: New 52-Wk High for CARA @ $4.700 up8.05% - Knobias



06/11/2003 (15:22 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +8.59% - Knobias


JS200

[js200]

Von Gestern,

CARA
CARACO PHARMACEUTICAL LABS INC
7.350
+0.870 +13.43%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 6/25/2003 (8) days ago, when the stock price was 6.100. Since then the stock gained 20.49% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 7.350
Previous Close 6.480
Change +0.870
% Change +13.43%
Volume 180,300
Stock Activity
Open 6.600
Day`s High 7.400
Day`s Low 6.480
52 Week High 7.350
52 Week Low 1.750


Stock Price History
3 Month % Change 145.00
6 Month % Change 172.22
12 Month % Change 153.45
Stock Statistics
50 Day Close MA 4.576
200 Day Close MA 3.202
65 Day Volume MA 74,169

JS200

[js200]

07/09/2003 (14:56 ET) VOLUME(+): CARA Volume 63% > 20-adsv, Stock +9.52% - Knobias
07/09/2003 (14:31 ET) 52W HIGH: New 52-Wk High for CARA @ $8.090 up10.07% - Knobias
07/07/2003 (12:12 ET) VOLUME(+): CARA Volume 24% > 20-adsv, Stock +5.44% - Knobias
07/07/2003 (10:04 ET) 52W HIGH: New 52-Wk High for CARA @ $7.450 up1.36% - Knobias
07/03/2003 (12:56 ET) 52W HIGH: New 52-Wk High for CARA @ $7.200 up11.11% - Knobias


JS200

[js200]

Einer meiner besten Tips

400% seit Oktober 2002

JS200

[js200]

Warmgelaufen, wird zurückkommen

07/09/2003 (16:23 ET) CLOSER(+): Last 90 Min, CARA Jumps +1.24%; Vol +64% - Knobias
07/09/2003 (14:56 ET) VOLUME(+): CARA Volume 63% > 20-adsv, Stock +9.52% - Knobias
07/09/2003 (14:31 ET) 52W HIGH: New 52-Wk High for CARA @ $8.090 up10.07% - Knobias
07/07/2003 (12:12 ET) VOLUME(+): CARA Volume 24% > 20-adsv, Stock +5.44% - Knobias
07/07/2003 (10:04 ET) 52W HIGH: New 52-Wk High for CARA @ $7.450 up1.36% - Knobias

JS200

[js200]

@MORCHEL

So um die 7 Dollar versuche ich nachzukaufen, was ist deine Meinung????

JS200

[js200]

Vom Freitag

CARA
CARACO PHARMACEUTICAL LABS INC
8.100
+0.100 +1.25%


Daily Commentary
BUY

Our system recommends BUY as of today. Previous SELL recommendation was made on 7/11/2003 (0) days ago, when the stock price was 8.100. Since then the stock gained 0.00% .

Today the stock closed higher, at its high (sign of strength) with a lower high and a lower low. The volume is low. The security price is trending up and is overbought.

The correction was very short, and the stock continues its rally. It is again time for bulls. Short positions should be closed immediately. Buy this stock now and hold it until the next sell signal. Long-term trend is bullish.

Candlestick Analysis

Today’s Candlestick Patterns:
Short White Candlestick
Harami Pattern

Today a Short White Candlestick formed. There was a limited price change that may represent consolidation.

The last two candlesticks formed a Harami Pattern. This is a neutral pattern which shows that the buying pressure may be diminishing. However, a confirmation, in the form of a gap down or weak close following this pattern is needed, for it to be considered bearish.

Stock Quote
Last 8.100
Previous Close 8.000
Change +0.100
% Change +1.25%
Volume 47,100
Stock Activity
Open 8.020
Day`s High 8.100
Day`s Low 7.800
52 Week High 8.150
52 Week Low 1.750

Stock Price History
3 Month % Change 217.65
6 Month % Change 198.89
12 Month % Change 194.55
Stock Statistics
50 Day Close MA 5.052
200 Day Close MA 3.346
65 Day Volume MA 86,095

JS200

[morchel]

js, ich lass sie einfach laufen!

vieleicht gehen sie bis 10 dann bin ich vollauf zufrieden!

morchel

[js200]

@MORCHEL

Dann lasse mer mal

JS200

[js200]

@MORCHEL

CARA
CARACO PHARMACEUTICAL LABS INC
7.950
-0.150 -1.85%


Daily Commentary
SELL

Our system recommends SELL as of today. Previous BUY recommendation was made on 7/14/2003 (0) days ago, when the stock price was 7.950. Since then the stock gained 0.00% .

Today the stock closed lower with an unchanged high and a higher low. The volume is low. The security price is trending up.


Long-term trend is bullish and it is strong. However, the correction seems to continue. The previous signal was probably a false one, but there is still a danger of a bear trap. You may sell this stock now and wait for the next buy signal.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 7.950
Previous Close 8.100
Change -0.150
% Change -1.85%
Volume 49,000
Stock Activity
Open 8.050
Day`s High 8.100
Day`s Low 7.900
52 Week High 8.150
52 Week Low 1.750

Stock Price History
3 Month % Change 205.77
6 Month % Change 183.93
12 Month % Change 183.93
Stock Statistics
50 Day Close MA 5.143
200 Day Close MA 3.377
65 Day Volume MA 86,078

JS200

[js200]

CARACO PHARM LABS - Nasdaq OTC BB: CARA

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time

Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
8.10 0.15 (1.89) 7.95 (5) 8.10 (5) 15:56
Day Volume Last Size Open High Low
59,600 800 7.95 8.10 7.90
Latest Ticks # of Trades Avg Trade Size VWAP 52 Wk High
+--+ 42 1,419 7.9562 8.44
52 Wk Low Prev Close Avg Day Vol
1.72 7.95 123,300
6:43:08 PM EDT - Tuesday, July 15, 2003- Exchange quote is delayed at least 15 minutes

JS200

[js200]

Hmmmmmm sieht schlecht aus, ich bin raus

JS200

[js200]

@MORCHEL

Halten die 8 Dollar, was meinst du

JS200

[morchel]

ich denke die 8 wird halten!

CARA ist für einen OTCBB Stock schon sehr hoch gelaufen!

Man darf nicht vergessen

CARA ist ein Generika Produzent!

Eine absolute Zukunftsbranche!

Ich denke das die OTCBB Zocker schon lange draussen sind und die Aktie in den Händen von Leuten sind die auf ein baldiges Listing an einer der Prime Börsen spekulieren!

schau dir mal CHAI an!
http://www.lifemedicalsciences.com/
zwar noch ealy stage aber trotzdem interessant. Hat auch mit Wunden zu tun. Operationswunden!

morchel

[js200]

Schlusskurs 8,20 Volumen 50.000

JS200

[morchel]

the Show mmust go on!

CARA scheint IN zu sein!

8,375

bid 8,4
ask 8,55



morchel

[js200]

@MORCHEL

Ich bin zwar draussen, aber es tut gut zu sehen, dass Sie wieder anläuft

JS200

[js200]

Caraco Pharmaceutical Reports Record Q2 2003, Midyear Results
via COMTEX

July 25, 2003

DETROIT, Jul 25, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) posted record results for the second quarter and first half of 2003, Narendra N. Borkar, Chief Executive Officer, reported today.

Q2 Results

Net income for the second quarter was $4,326,158, or $0.17 per diluted share, a sharp turnaround from a net loss of $1,909,840, $0.08 per diluted share, for the second quarter of 2002. Both gross and operating income also improved appreciably. Gross profit rose 144% to $7,462,473, from $3,061,528 a year ago. The operating profit was $4,695,649, up 406% from Q2-2002 operating loss of $1,534,406.

Revenues for the quarter rose a robust 111% to $11,889,937, from $5,627,449 a year ago. Q2 revenues rose 36% over Q1 revenues of $8,721,600.

Six-month results

Midyear results were exceptional, as well. Net income jumped to $6,530,906, or $0.26 per diluted share, from a year earlier net loss of $2,429,533, or $0.11 per diluted share. The gross profit improved to $11,958,124 from $4,515,940 for the first six months of 2002. Operating profit improved similarly, rising to $7,341,585, from an operating loss of $1,685,971, a year ago.

Revenues for the first half jumped 131% to $20,611,537, from year-earlier revenues of $8,929,408.

Mr. Borkar said, `We are proud of our results for the second quarter and first half of 2003. Our gross margin and net income were substantially improved, reflecting higher sales, manufacturing efficiencies and larger production batches. The favorable results also underscore the success of our efforts in new product introduction and vertical-integration and the purchase of raw materials and active substances at highly competitive prices. Much of the credit for these accomplishments goes to our affiliate, Sun Pharmaceutical Industries, which is an FDA-approved supplier of certain active substances.

`In addition to the substantial growth in sales and strong profitability, we introduced one new drug, clozapine, a generic form of Clozaril, during the quarter. This raises our formulary to 16 drugs.

`Looking forward, we are optimistic about the third quarter and second half of 2003. We expect continued growth in sales and strong gross-profit margins in the third and fourth quarters. As reported, our sales for the year are expected to increase more than 50% to $35 million. We, likewise, expect profitability in quarters in which we do not recognize technology transfer expenses for new drugs under our R&D agreement with Sun Pharma.

`We plan to introduce one new drug, digoxin, a generic form of Lanoxin, in the third quarter. By yearend, we expect to receive two or three drug approvals from the FDA,`he said. He noted that the Company has 15 drugs in various stages of development.

Caraco has received FDA approval for 10 generic drugs over the past two years. These are: digoxin, a generic form of Glaxo Wellcome`s Lanoxin; clozapine, a generic form of Novartis`Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies. Sun Pharmaceutical Industries Ltd. is India`s fifth largest pharmaceutical company and owns about one-half of Caraco`s outstanding shares of common stock.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risk factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risk factors and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Corporation assumes no responsibility to update forward-looking statements.

(unaudited) Six Months Ended June 30 Three Months ended June 30 2003 2002 2003 2002 Net Sales 20,611,537 8,929,408 11,889,937 5,627,449 Cost of goods sold 8,929,408 4,413,468 4,427,464 2,565,921 Gross Profit 11,958,124 4,515,940 7,462,473 3,061,528 Selling, general & administrative expenses 3,089,820 1,839,689 2,140,036 1,084,584 R&D Cost 1,526,719 1,571,502 720,630 3,511,350 R&D Cost to affiliate 2,790,720 2,790,720 Operating income/ (loss) 7,341,585 (1,685,971) 4,695,649 (1,534,406) Interest Interest expense (817,722) (745,982) (375,470) (376,915) Interest income 7,044 2,420 5,978 1,481 Net interest expense (810,679) (743,562) (369,492) (375,434) Net income/(loss) 6,530,906 (2,429,533) 4,326,158 (1,909,840) Net income/(loss) per diluted common share 0.26 (0.11) 0.17 (0.08)
SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical (CARA)

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[morchel]

js, schade 10,25 +22%

DETROIT, Jul 25, 2003 /PRNewswire-FirstCall via COMTEX/ --
Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) posted record results for the second quarter and first half of 2003, Narendra N. Borkar, Chief Executive Officer, reported today.

Q2 Results

Net income for the second quarter was $4,326,158, or $0.17 per diluted share, a sharp turnaround from a net loss of $1,909,840, $0.08 per diluted share, for the second quarter of 2002. Both gross and operating income also improved appreciably. Gross profit rose 144% to $7,462,473, from $3,061,528 a year ago. The operating profit was $4,695,649, up 406% from Q2-2002 operating loss of $1,534,406.

Revenues for the quarter rose a robust 111% to $11,889,937, from $5,627,449 a year ago. Q2 revenues rose 36% over Q1 revenues of $8,721,600.

Six-month results

Midyear results were exceptional, as well. Net income jumped to $6,530,906, or $0.26 per diluted share, from a year earlier net loss of $2,429,533, or $0.11 per diluted share. The gross profit improved to $11,958,124 from $4,515,940 for the first six months of 2002. Operating profit improved similarly, rising to $7,341,585, from an operating loss of $1,685,971, a year ago.

Revenues for the first half jumped 131% to $20,611,537, from year-earlier revenues of $8,929,408.

Mr. Borkar said, `We are proud of our results for the second quarter and first half of 2003. Our gross margin and net income were substantially improved, reflecting higher sales, manufacturing efficiencies and larger production batches. The favorable results also underscore the success of our efforts in new product introduction and vertical-integration and the purchase of raw materials and active substances at highly competitive prices. Much of the credit for these accomplishments goes to our affiliate, Sun Pharmaceutical Industries, which is an FDA-approved supplier of certain active substances.

`In addition to the substantial growth in sales and strong profitability, we introduced one new drug, clozapine, a generic form of Clozaril, during the quarter. This raises our formulary to 16 drugs.

`Looking forward, we are optimistic about the third quarter and second half of 2003. We expect continued growth in sales and strong gross-profit margins in the third and fourth quarters. As reported, our sales for the year are expected to increase more than 50% to $35 million. We, likewise, expect profitability in quarters in which we do not recognize technology transfer expenses for new drugs under our R&D agreement with Sun Pharma.

`We plan to introduce one new drug, digoxin, a generic form of Lanoxin, in the third quarter. By yearend, we expect to receive two or three drug approvals from the FDA,`he said. He noted that the Company has 15 drugs in various stages of development.

Caraco has received FDA approval for 10 generic drugs over the past two years. These are: digoxin, a generic form of Glaxo Wellcome`s Lanoxin; clozapine, a generic form of Novartis`Clozaril; ticlopidine hydrochloride, a generic form of Hoffman LaRoche`s Ticlid; meperidine hydrochloride, a generic form of Sanofi-Synthelabo`s Demerol; metformin hydrochloride, a generic form of Bristol Myers Squibb`s Glucophage; oxaprozin, a generic form of G.D. Searle`s Daypro; carbamazepine (chewable), a generic form of Novartis` Tegretol; clonazepam, a generic form of Roche`s Klonopin; flurbiprofen, a generic form of Pharmacia`s Ansaid; and tramadol hydrochloride, a generic form of R.W. Johnson Pharma Research Institute`s Ultram.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies. Sun Pharmaceutical Industries Ltd. is India`s fifth largest pharmaceutical company and owns about one-half of Caraco`s outstanding shares of common stock.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risk factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risk factors and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Corporation assumes no responsibility to update forward-looking statements.

(unaudited) Six Months Ended June 30 Three Months ended June 30 2003 2002 2003 2002 Net Sales 20,611,537 8,929,408 11,889,937 5,627,449 Cost of goods sold 8,929,408 4,413,468 4,427,464 2,565,921 Gross Profit 11,958,124 4,515,940 7,462,473 3,061,528 Selling, general & administrative expenses 3,089,820 1,839,689 2,140,036 1,084,584 R&D Cost 1,526,719 1,571,502 720,630 3,511,350 R&D Cost to affiliate 2,790,720 2,790,720 Operating income/ (loss) 7,341,585 (1,685,971) 4,695,649 (1,534,406) Interest Interest expense (817,722) (745,982) (375,470) (376,915) Interest income 7,044 2,420 5,978 1,481 Net interest expense (810,679) (743,562) (369,492) (375,434) Net income/(loss) 6,530,906 (2,429,533) 4,326,158 (1,909,840) Net income/(loss) per diluted common share 0.26 (0.11) 0.17 (0.08)
SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical (CARA)

Copyright (C) 2003 PR Newswire. All rights reserved.

morchel

[js200]

Caraco Pharmaceutical Laboratories Corrects Q2 R&D Expense
via COMTEX

July 25, 2003

DETROIT, Jul 25, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) says R&D costs for the second quarters of 2003 and 2002 in today`s news release should have been $626,788 for Q2 2003 and $720,630 for Q2 2002. In today`s news release, those expenses were reported as $720,630 and $3,511,350, respectively.

Earnings were not changed.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, and healthcare systems.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Corporation assumes no responsibility to update forward- looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CARA)

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[morchel]

morchel

[js200]

@Morchel

400% hatten mir gereicht, heute wärens 500%, leider, aber man kann nicht immer gewinnen

JS200

[js200]

10,65 Dollar, Schei..e

JS200

[js200]

Caraco Pharmaceutical Laboratories Corrects Q2 R&D Expense

EPS Unchanged

Friday , July 25, 2003 12:52 ET

DETROIT, Jul 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) says R&D costs for the second quarters of 2003 and 2002 in today`s news release should have been $626,788 for Q2 2003 and $720,630 for Q2 2002. In today`s news release, those expenses were reported as $720,630 and $3,511,350, respectively.

Earnings were not changed.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, and healthcare systems.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Corporation assumes no responsibility to update forward- looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.


CONTACT: Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical,
[phone]; or Mike Marcotte of Marcotte Financial Relations,
[phone], for Caraco Pharmaceutical Laboratories, Ltd.
(CARA)

http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: Michigan
INDUSTRY KEYWORD: MTC
OTC
SUBJECT CODE: ERN
OTC


STOCK SYMBOLS: [(cara)]

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/25/2003 (12:52 ET) Caraco Pharmaceutical Laboratories Corrects Q2 R&D Expense - PR Newswire



07/25/2003 (11:07 ET) VOLUME(+): CARA Volume 15% > 20-adsv, Stock +11.04% - Knobias



07/25/2003 (10:19 ET) 52W HIGH: New 52-Wk High for CARA @ $8.850 up5.67% - Knobias



07/25/2003 (10:18 ET) ERN(+): CARA/Q2 17c vs (8c); EPS +312% Y/Y; Provides Guidance - Knobias



07/25/2003 (09:56 ET) Caraco Pharmaceutical Reports Record Q2 2003, Midyear Results - PR Newswire



07/24/2003 (10:48 ET) 52W HIGH: New 52-Wk High for CARA @ $8.450 up3.06% - Knobias



07/09/2003 (16:23 ET) CLOSER(+): Last 90 Min, CARA Jumps +1.24%; Vol +64% - Knobias



07/09/2003 (14:56 ET) VOLUME(+): CARA Volume 63% > 20-adsv, Stock +9.52% - Knobias



07/09/2003 (14:31 ET) 52W HIGH: New 52-Wk High for CARA @ $8.090 up10.07% - Knobias



07/07/2003 (12:12 ET) VOLUME(+): CARA Volume 24% > 20-adsv, Stock +5.44% - Knobias



07/07/2003 (10:04 ET) 52W HIGH: New 52-Wk High for CARA @ $7.450 up1.36% - Knobias



07/03/2003 (12:56 ET) 52W HIGH: New 52-Wk High for CARA @ $7.200 up11.11% - Knobias



07/03/2003 (11:51 ET) VOLUME(+): CARA Volume 29% > 20-adsv, Stock +8.02% - Knobias



07/01/2003 (15:36 ET) VOLUME(+): CARA Volume 96% > 20-adsv, Stock +7.10% - Knobias



07/01/2003 (09:48 ET) 52W HIGH: New 52-Wk High for CARA @ $6.650 up0.45% - Knobias



06/30/2003 (15:41 ET) 52W HIGH: New 52-Wk High for CARA @ $6.570 up1.86% - Knobias



06/27/2003 (11:16 ET) 52W HIGH: New 52-Wk High for CARA @ $6.250 up3.31% - Knobias


JS200

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
10.650
+2.275 +27.16%


Daily Commentary
BUY

Our system recommends BUY as of today. Previous SELL recommendation was made on 7/17/2003 (8) days ago, when the stock price was 8.000. Since then the stock gained 33.13% .

Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is extremely high. The security price is trending up and is overbought.


The correction is over and the stock is starting a new rally. It is again time for bulls. You may make hefty profits if you buy this stock now and hold it until the next sell signal. Long-term trend is also bullish.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 10.650
Previous Close 8.375
Change +2.275
% Change +27.16%
Volume 734,200
Stock Activity
Open 8.550
Day`s High 10.650
Day`s Low 8.400
52 Week High 10.650
52 Week Low 1.750

Stock Price History
3 Month % Change 251.49
6 Month % Change 218.86
12 Month % Change 290.11
Stock Statistics
50 Day Close MA 5.903
200 Day Close MA 3.672
65 Day Volume MA 96,197

JS200

[js200]

11,35 Dollar

JS200

[morchel]

11,50 war das tageshoch!

Schluß:11,06

morchel

[js200]

@MORCHEL

Bei 8,4 komm ich wieder

JS200

[js200]

@MORCHEL

Bald bin ich wieder drin

Last Trade: 9.650 Change: -1.410 (-12.749%)
Previous Close: 11.060 Volume: 154,100
Bid: 9.550 Ask: 9.650
Today`s Open: 10.950 # of Trades: 208


JS200

[MRASTA]

melde mich aus dem Urlaub zurück. Wie erfreulich.

Und nun dieses, denn mal hüh.

Warum seit ihr übrigends ausgestiegen ?


July 31, 2003 13:16

Caraco Pharmaceutical Laboratories Files for AMEX Listing, Raises 2003 Guidance to $42 Million
Jump to first matched term

DETROIT, July 31 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (OTC Bulletin Board: CARA) has filed an application for listing of its common stock on the American Stock Exchange (Amex), Narendra N. Borkar, Chief Executive Officer, announced today.

Mr. Borkar also announced that the Company has raised its 2003 revenue guidance to $42 million. The new 2003 guidance is 88% above 2002`s reported revenues of $22.4 million.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, and healthcare systems.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission, available free via EDGAR. The Corporation assumes no responsibility to update forward- looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

/CONTACT: Narendra Borkar or Bob Kurkiewicz of Caraco Pharmaceutical
Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial
Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd./

(CARA)

Gruß
mrasta

[js200]

07/31/2003 (16:37 ET) VOLUME(+): CARA Volume 93% > 20-adsv, Stock +9.60% - Knobias
07/31/2003 (14:21 ET) 52W HIGH: New 52-Wk High for CARA @ $11.600 up17.17% - Knobias
07/31/2003 (14:01 ET) 8-K: CARA Files Jul-25 PR Regarding Q2 2003 Financial Results - Knobias
07/31/2003 (13:56 ET) New 8-K just released for CARA - Edgar
07/31/2003 (13:16 ET) Caraco Pharmaceutical Laboratories Files for AMEX Listing, Raises 2003 Guidance to $42 Million - PR Newswire


JS200

[js200]

Vom Freitag

CARA
CARACO PHARMACEUTICAL LABS INC
10.500
-0.350 -3.23%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 7/31/2003 (1) days ago, when the stock price was 10.850. Since then the stock fell -3.23% .

Today the stock closed lower, at its low (sign of weakness) with a lower high and a higher low (sign of decrease in volatility). The volume is low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 10.500
Previous Close 10.850
Change -0.350
% Change -3.23%
Volume 58,000
Stock Activity
Open 11.200
Day`s High 11.250
Day`s Low 10.500
52 Week High 11.060
52 Week Low 1.750

Stock Price History
3 Month % Change 208.82
6 Month % Change 165.82
12 Month % Change 288.89
Stock Statistics
50 Day Close MA 6.532
200 Day Close MA 3.885
65 Day Volume MA 104,163

JS200

[2 PAC]

endlich mal ein vernünftiger wert, den ihr hier bespricht! CARA könnte in die fußstapfen von LCI und MED treten, viel erfolg!

2 PAC

[js200]

08/08/2003 (16:57 ET) New 10QSB just released for CARA - Edgar
08/08/2003 (09:04 ET) New 4/A just released for CARA - Edgar
08/08/2003 (08:34 ET) New 4 just released for CARA - Edgar
08/07/2003 (07:49 ET) New 4 just released for CARA - Edgar
08/06/2003 (10:15 ET) New 4 just released for CARA - Edgar


JS200

[js200]

@2PAC

Bin vor einem Jahr draufgestossen und habe mit 400% im Plus den Ausstieg gemacht.

Komme aber um die 8,50 Dollar wieder rein

JS200

[js200]

OPS Rating Upgrade for Caraco Pharmaceutical
via CDS

August 14, 2003

Caraco Pharmaceutical Laboratories, Ltd. (OTC:CARA) reported positive OPS (Operational-cashflow Per Share) for its quarter ended June 30, 2003 and StockDiagnostics.com has upgraded its OPS Rating to `2`from its previous OPS Rating of `6`. Caraco Pharmaceutical`s OPS Rating of `2`is its highest over its previous six years.



The OPS RatingTM upgrade was based on Caraco Pharmaceutical`s recently filed Cash Flow Statements for its quarter ended June 30, 2003. The company`s computed OPS TM (Operational-cashflow Per Share) for the quarter was $0.21 per share as compared to $-0.03 per share for the comparable year earlier quarter. OPS for the most recent 12 months ended June 30, 2003 was $0.23 per share as compared to $-0.30 per share for the 12 months ended June 30, 2002. OPS for Caraco Pharmaceutical`s trailing twelve months reached a five year high.



The shares of Caraco Pharmaceutical were recently trading at $10.97 which is within 7% of their ten year high of $11.70 on July 31, 2003.



StockDiagnostics.com has issued 1668 OPS Rating upgrades for 2003. This compares with 2059 OPS Rating upgrades in the same period last year. For all of 2002, there were 3761 OPS Rating upgrades.



About OPS RatingsTM changes -- OPS Rating upgrades and downgrades may predict changes in the momentum of a company`s stock price and its inherent or presumed financial health. All OPS Rating downgrades, even a downgrade from the highest OPS Rating of `1`to the second highest OPS Rating of `2`should be treated with equal caution. Similarly, all OPS Rating upgrades should be considered as equally positive. Even an upgrade from the lowest OPS Rating of `8`to the second lowest OPS Rating of `7`can be treated with guarded optimism.



About OPS RatingsTM -- StockDiagnostics.com monitors Operational cash flow Per Share (`OPS`) for over 7,000 publicly traded companies and assigns them an `OPS Rating`, which measures the long term risk associated with a company`s ability to remain in business. A company`s `OPS`logically falls into a mathematical sequence that ranks it into one of eight distinctive `risk`categories. Each of the categories is based on a company`s operating cash flow for each of its last 4 quarters and its cumulative operating cash flow for its most recent 12 months. OPS Ratings are upgraded, downgraded or reiterated each time a company files a quarterly report and at any time that its financial statements are amended. Statistical research on OPS Ratings is available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.



About StockDiagnostics.com -- StockDiagnostics.com monitors 1,801 data points on over 10,000 publicly traded companies. It has a proprietary data refinery that automates the process of collecting, sorting and organizing large amounts of securities pricing and financial data into comparative financial ratios. These ratios are used to identify Financial Statement anomalies and securities pricing variances to monitor changes in the performance of public companies. Go to http://www.StockDiagnostics.com/marketnews for a description of StockDiagnostics.com`s patent-pending technical applications, such as OPS, OPS Ratings, The EPS Syndrome and more. Full details are available at http://www.StockDiagnostics.com/marketnews." target="_blank" rel="nofollow ugc noopener">http://www.StockDiagnostics.com/marketnews.

JS200

[fonx]

Ich hätte sie doch bei 2.40 kaufen sollen!!!!!!!!!!!! FONX

[js200]

@FONX

Du glaubst mir ja nie

JS200

[fonx]

Schon,Lamp hatte mich mehr überzeugt,bin gespannt was noch geht???????? FONX

[js200]

Von Gestern

CARA
CARACO PHARMACEUTICAL LABS INC
10.750
+0.240 +2.28%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 7/31/2003 (15) days ago, when the stock price was 10.850. Since then the stock fell -0.92% .

Today the stock closed higher with a lower high and a higher low (sign of decrease in volatility). The volume is extremely low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 10.750
Previous Close 10.510
Change +0.240
% Change +2.28%
Volume 37,400
Stock Activity
Open 10.840
Day`s High 10.900
Day`s Low 10.600
52 Week High 11.060
52 Week Low 1.750

Stock Price History
3 Month % Change 141.57
6 Month % Change 207.14
12 Month % Change 293.77
Stock Statistics
50 Day Close MA 7.827
200 Day Close MA 4.304
65 Day Volume MA 96,971

JS200

[MRASTA]

August 19, 2003 08:33

Caraco Pharmaceutical Laboratories Shares To Move To Amex
Jump to first matched term

New Symbol: CPD

DETROIT, Aug. 19 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced that its common stock will begin trading today on the American Stock Exchange (Amex.)

The shares will trade on the Amex under the new symbol CPD. Caraco`s shares have traded on the OTCBB under the symbol CARA.

Narendra N. Borkar, CEO, said, "The move to the Amex is intended to increase the stock`s visibility and liquidity. We expect the shares will be listed in financial publications such as the Wall Street Journal, Investor`s Business Daily, Barron`s and others that report share information from AMEX and the other major exchanges. In addition, our move up to Amex qualifies our shares to be purchased by a wider range of investors, including institutions, many of which restrict purchases to companies listed on the major exchanges."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include: that information is of a preliminary nature and may be subject to further adjustment, not obtaining FDA approval for new products or delays in receiving FDA approvals, governmental restrictions on the sale of certain products, dependence on key personnel, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launch, integrity and reliability of the Company`s data, lack of success of attaining full compliance with regard to regulatory and cGMP compliance, and other risks identified from time to time in the Company`s reports and registration statements filed with the SEC. The Corporation assumes no responsibility to update forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

[js200]

Caraco Pharmaceutical Labs Ltd (AMEX:CPD)

JS200

[js200]

Last Trade: 12.100 Change: 0.600 (+5.217%)
Previous Close: 11.500 Volume: 105,100
Bid: N/A Ask: N/A
Today`s Open: 11.500 # of Trades: 99


08/26/2003 (14:16 ET) 52W HIGH: New 52-Wk High for CPD @ $12.000 up4.35% - Knobias
08/25/2003 (16:44 ET) New 4 just released for CPD - Edgar
08/25/2003 (14:42 ET) 52W HIGH: New 52-Wk High for CPD @ $11.790 up9.17% - Knobias
08/21/2003 (07:44 ET) New 4 just released for CPD - Edgar
08/19/2003 (09:38 ET) American Stock Exchange Lists Common Stock Of Caraco Pharmaceutical Laboratories, Ltd. - PR Newswire

JS200

[js200]

Caraco CEO to Retire/Remain on Board
via COMTEX

August 27, 2003

DETROIT, Aug 27, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced today that its Chief Executive Officer, Narendra N. Borkar, 62, will retire at the end of the quarter. He will remain a director of Caraco Pharmaceutical Laboratories, Ltd. Jitendra N. Doshi, 52, who is a director and has served as Caraco`s Chief Operating Officer since June 2001, will assume duties as interim Chief Executive Officer of Caraco Pharmaceutical.

Mr. Borkar joined Caraco in August 1997 from Ciba Geigy, now Novartis, where he headed its pharmaceutical business in India.

Mr. Doshi joined Caraco from Sun Pharmaceutical Industries where he served as General Manager-Operations. Prior to joining Sun Pharmaceutical in 1999, he was promoter and Managing Director of an Indian manufacturing company.

The Company has forecast 2003 sales of $42 million, an 88% jump over 2002`s reported revenues of $22.4 million.

In making the announcement, Dilip S. Shanghvi, Caraco`s Chairman, noted, `Mr. Borkar has been an integral part of our Company`s turnaround, growth, and success. He will remain on the board of Caraco and continue to contribute to Caraco. We wish him and his family the very best. We have high expectations for the entire Caraco team and Mr. Doshi, especially given his strong experience in the pharmaceutical industry and solid grounding in manufacturing.`

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include, among other factors, that information is of a preliminary nature and may be subject to further adjustment, not obtaining FDA approval for new products or delays in receiving FDA approvals, governmental restrictions on the sale of certain products, dependence on key personnel, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launch, integrity and reliability of the Corporation`s data, lack of success of attaining full compliance with regard to regulatory and cGMP compliance, and other risks identified from time to time in the Corporation`s reports and registration statements filed with the SEC. The Corporation assumes no responsibility to update forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar, Jitendra Doshi or Bob Kurkiewicz, all of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CPD)

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[fonx]

Wenn bedenkt das dieser Thread ein Schattendasein führt,im Gegensatz zum Kursverlauf,hätte doch jaufen sollen!!!!!!!!!!!!!!!!FONX

[morchel]

Viele Blumen Blühen eben im verborgenen!



morchel

[js200]

09/04/2003 (10:20 ET) VOLUME(-): CPD Volume 20% > 20-adsv, Stock -14.52% - Knobias
09/03/2003 (17:18 ET) New 4 just released for CPD - Edgar
09/03/2003 (15:02 ET) VOLUME(-): CPD Volume 67% > 20-adsv, Stock -5.22% - Knobias
08/28/2003 (16:43 ET) New 4 just released for CPD - Edgar
08/28/2003 (15:58 ET) New 4 just released for CPD - Edgar


JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


09/22/2003 (13:46 ET) New 4/A just released for CPD - Edgar



09/22/2003 (13:32 ET) New 4/A just released for CPD - Edgar



09/22/2003 (13:27 ET) New 4/A just released for CPD - Edgar



09/22/2003 (13:14 ET) New 4/A just released for CPD - Edgar



09/22/2003 (09:25 ET) 1Source4Stocks Reports on CPD - Knobias



09/19/2003 (16:15 ET) CPD: Short Interest UP 100.0% to 136.1K in Sep 2003 - Knobias



09/18/2003 (15:43 ET) New 4/A just released for CPD - Edgar



09/18/2003 (15:33 ET) New 4 just released for CPD - Edgar



09/18/2003 (14:51 ET) New 4 just released for CPD - Edgar



09/15/2003 (14:34 ET) New 4/A just released for CPD - Edgar



09/15/2003 (14:27 ET) New 4/A just released for CPD - Edgar



09/15/2003 (14:15 ET) New 4 just released for CPD - Edgar



09/15/2003 (10:27 ET) New 4 just released for CPD - Edgar



09/15/2003 (08:01 ET) New 4 just released for CPD - Edgar



09/04/2003 (10:20 ET) VOLUME(-): CPD Volume 20% > 20-adsv, Stock -14.52% - Knobias



09/03/2003 (17:18 ET) New 4 just released for CPD - Edgar



09/03/2003 (15:02 ET) VOLUME(-): CPD Volume 67% > 20-adsv, Stock -5.22% - Knobias



08/28/2003 (16:43 ET) New 4 just released for CPD - Edgar



08/28/2003 (15:58 ET) New 4 just released for CPD - Edgar



08/27/2003 (16:19 ET) Caraco CEO to Retire/Remain on Board - PR Newswire



08/26/2003 (14:16 ET) 52W HIGH: New 52-Wk High for CPD @ $12.000 up4.35% - Knobias



08/25/2003 (16:44 ET) New 4 just released for CPD - Edgar



08/25/2003 (14:42 ET) 52W HIGH: New 52-Wk High for CPD @ $11.790 up9.17% - Knobias


JS200

[js200]

Caraco Pharmaceutical Laboratories Receives FDA Approval For Tizanidine Hydrochloride
via COMTEX

September 30, 2003

DETROIT, Sep 30, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market tizanidine hydrochloride, a generic form of Elan Pharmaceutical`s Zanaflex, Narendra N. Borkar, Chief Executive Officer, announced today.

Tizanidine is a short-acting muscle relaxant prescribed for the management of spasticity and has a U.S. market of approximately $240 million.

He noted that the Company has two additional drugs pending FDA approval.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include: information is of a preliminary nature and may be subject to further adjustment, not obtaining or delays in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, dependence on key personnel, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, integrity and reliability of the Corporation`s data, lack of success of attaining full compliance with regard to regulatory and cGMP compliance, and other risks identified from time to time in the Corporation`s reports and registration statements filed with the SEC, available free via EDGAR. The Corporation assumes no responsibility to update forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Narendra Borkar, Jitendra Doshi, or Bob Kurkiewicz of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CPD)

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[js200]

09/30/2003 (10:28 ET) CPD Receives FDA Approval for Generic Zanaflex - Knobias
09/30/2003 (10:00 ET) Caraco Pharmaceutical Laboratories Receives FDA Approval For Tizanidine Hydrochloride - PR Newswire
09/23/2003 (19:21 ET) New 4 just released for CPD - Edgar
09/22/2003 (13:46 ET) New 4/A just released for CPD - Edgar
09/22/2003 (13:32 ET) New 4/A just released for CPD - Edgar


JS200

[js200]

Caraco Pharmaceutical Laboratories Director Retires
via COMTEX

October 2, 2003

DETROIT, Oct 2, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) announced today that David A. Hagelstein, 62, has retired from its board of directors to pursue personal business interests which will preclude him from devoting sufficient time to Caraco. Mr. Hagelstein stated that he was pleased with the direction and progress of the Company and that he was pleased to be leaving the Company in a stronger position than when he joined the board in 1995.

Jitendra N Doshi, CEO, said, `Mr. Hagelstein has been a valued advisor to the Company and has been integral to the Company`s turnaround and progress. All of us wish him the very best both personally and professionally in his numerous business endeavors.`

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include, among other factors, that information is of a preliminary nature and may be subject to further adjustment, not obtaining FDA approval for new products or delays in receiving FDA approvals, governmental restrictions on the sale of certain products, dependence on key personnel, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launch, integrity and reliability of the Corporation`s data, lack of success of attaining full compliance with regard to regulatory and cGMP compliance, and other risks identified from time to time in the Corporation`s reports and registration statements filed with the SEC. The Corporation assumes no responsibility to update forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Jitendra Doshi or Bob Kurkiewicz of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CPD)

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Kommt wieder die Zeit einzusteigen ???????

JS200

[js200]

10/08/2003 (18:22 ET) New 4 just released for CPD - Edgar
10/02/2003 (16:29 ET) Caraco Pharmaceutical Laboratories Director Retires - PR Newswire
10/01/2003 (11:41 ET) New 4 just released for CPD - Edgar
09/30/2003 (10:28 ET) CPD Receives FDA Approval for Generic Zanaflex - Knobias
09/30/2003 (10:00 ET) Caraco Pharmaceutical Laboratories Receives FDA Approval For Tizanidine Hydrochloride - PR Newswire

JS200

[js200]

Caraco Pharma Posts $32.9 Million 9-Month Sales
via COMTEX

October 15, 2003

DETROIT, Oct 15, 2003 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) posted its third consecutive quarter of profitability and record sales for the third quarter and the nine months ended September 30, 2003, Jitendra Doshi, Chief Executive Officer, reported today.

Third-quarter results. Net income for the quarter ended September 30, 2003 rose 540% to $4.54 million, from year-earlier net income of $0.7 million, or $0.03 per share. The strong earnings growth came from a rise in sales. Net sales for the quarter ended September 30, 2003 rose 108% to a record $12.3 million, from $5.9 million for the corresponding period in 2002.

Gross profit for the quarter ended September 30, 2003 was $7.84 million, significantly better than the $2.86 million recorded for the corresponding period in 2002. Operating income similarly improved, rising 337% to $4.74 million in the quarter ended September 30, 2003, from $1.09 million for the corresponding period in 2002.

Nine-month results. Nine-month results were equally positive. Net income for the nine months ended September 30, 2003 rose to $11.07 million, or $0.44 per diluted share, from a net loss of $1.72 million or $0.08 per diluted share for the corresponding period in 2002.

Sales were ahead of plan. Net sales for the nine months ended September 30, 2003 rose 122% to a record $32.9 million, from $14.83 million for the corresponding period in 2002.

Gross profit for the nine months ended September 30, 2003 reached $19.79 million, from $7.38 million for the corresponding period in 2002.

Operating income for the nine months ended September 30, 2003 was $12.08 million, versus an operating loss of $0.6 million for the corresponding period in 2002. However, the operating loss for the nine months ended September 30, 2002 included non-cash research and development expenses of approximately $2.8 million relating to 1,088,000 shares earned by Sun Pharmaceutical Industries Limited (`Sun Pharmaceutical`) in connection with two products transferred to the Company by Sun Pharmaceutical pursuant to its then existing products agreement with the Company. In comparison, there were no non-cash research and development expenses for the nine months ended September 30, 2003.

The Company has not filed any new ANDAs with the FDA for approval during the nine months ended September 30, 2003. In addition, the Company does not expect to file any new ANDAs with the FDA for approval during the fourth quarter of 2003.

Although Sun Global and the Company entered into a products agreement in November 2002 (the `Products Agreement`), since such date, no products have yet been selected and agreed upon by the Company, the Independent Committee of Directors of the Company and Sun Global. While they are engaged in discussions, the Company has decided to perform research and development for certain products (`Products`) (currently six) presented for consideration by Sun Global pursuant to the Products Agreement. However, if the Company does not select and accept any of such Products for itself for filing as ANDAs with the FDA, Sun Global will reimburse the Company for all of its research and development and other costs associated with such Product. Sun Global may then file the ANDA with the FDA in its name, and the Company and Sun Global may negotiate an agreement pursuant to which the Company will manufacture and market the Product. The consideration payable to the Company will be no less favorable than what unrelated third parties would receive.

Mr. Doshi said, `The third quarter was very positive for our Company and we are optimistic about the fourth quarter, and we are revising upward our sales guidance for the year to $45 million, which would represent a doubling of sales from 2002`s $22.4 million.`

The Company received approval last month from the U.S. Food and Drug Administration (FDA) to manufacture and market tizanidine hydrochloride, a generic form of Elan Pharmaceutical`s Zanaflex. Tizanidine is a short-acting muscle relaxant prescribed for the management of spasticity and has a U.S. market of approximately $240 million. The Company`s formulary now stands at 17 drugs. Two additional drugs are pending FDA approval.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s largest wholesalers and distributors, drugstore chains and healthcare systems. The Company is affiliated with Mumbai, India-based Sun Pharmaceutical, India`s fifth largest pharmaceutical company. Sun Pharmaceutical holds approximately 49% of Caraco`s common stock.

Safe Harbor. This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include: information is of a preliminary nature and may be subject to adjustment, not obtaining or delays in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, dependence on key personnel, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, integrity and reliability of the Corporation`s data, lack of success of attaining full compliance with regard to regulatory and cGMP compliance, and other risks identified from time to time in the Corporation`s reports and registration statements filed with the SEC, available free via EDGAR. The Corporation assumes no responsibility to update forward-looking statements.

CARACO PHARMACEUTICAL LABORATORIES, LTD. UNAUDITED STATEMENTS OF OPERATIONS PARTICULARS NINE MONTHS ENDED THREE MONTHS ENDED 30-Sep 30-Sep 2003 2002 2003 2002 Net Sales 32,905,662 14,828,849 12,294,125 5,899,441 Cost of goods sold 13,112,198 7,448,809 4,458,785 3,035,340 Gross profit 19,793,465 7,380,040 7,835,341 2,864,101 Selling, general & administrative expenses 5,689,566 2,648,202 2,599,746 808,963 R&D cost 2,018,029 2,541,449 491,310 969,947 R&D cost - Affiliate - 2,790,720 - - Operating income / (loss) 12,085,870 (600,331) 4,744,285 1,085,191 Interest Interest expense (1,041,382) (1,130,898) (223,660) (384,917) Interest income 24,790 10,798 17,747 8,377 Net interest expense (1,016,593) (1,120,100) (205,914) (376,540) Net income / (loss) 11,069,278 (1,720,431) 4,538,371 708,651 Net income / (loss) per common share Basic 0.46 (0.08) 0.19 0.03 Diluted 0.44 (0.08) 0.18 0.03
SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Jitendra Doshi or Bob Kurkiewicz of Caraco Pharma, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CPD)

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Ist doch gut gewesen, dass ich bei 8 Dollar wieder rein bin, dann lauf mal schön kleine CARA

01/26/2004 (10:49 ET) CPD: Volume Spike; 19% > 20-adsv, Stock +6.29% - Knobias
01/26/2004 (10:25 ET) CPD: New 52-Wk High @ $12.230 up 4.00% - Knobias
01/23/2004 (19:22 ET) CPD: Filed New Form 4 - Edgar
01/23/2004 (19:12 ET) CPD: Filed New Form 3 - Edgar
01/23/2004 (18:52 ET) CPD: Filed New Form 4 - Edgar

Last Trade: 13.030 Change: 1.270 (+10.799%)
Previous Close: 11.760 Volume: 433,000
Bid: N/A Ask: N/A
Today`s Open: 11.990 # of Trades: 449

JS200

[js200]

01/27/2004 (10:21 ET) CPD: Volume Spike; 26% > 20-adsv, Stock -10.38% - Knobias
01/27/2004 (09:00 ET) Caraco Meets $45 Million Revenue Target for 2003 - PR Newswire
01/26/2004 (10:49 ET) CPD: Volume Spike; 19% > 20-adsv, Stock +6.29% - Knobias
01/26/2004 (10:25 ET) CPD: New 52-Wk High @ $12.230 up 4.00% - Knobias
01/23/2004 (19:22 ET) CPD: Filed New Form 4 - Edgar

JS200

[js200]

Wenn ich dieses heute ansehe, kaum zuglauben was aus CARA wurde !!!!!!!!!


Caraco Pharmaceutical Labs Ltd (AMEX:CPD)
As of 04-03-2004 ( 16:18 ET )
Basic Profile | SEC Filings | Technical Analysis | Chart | News
Messages | Most Actives | JOIN KNOBIAS


Business Summary: CURRENT BUSINESS INFORMATION: Caraco Pharmaceutical Laboratories, Ltd. is engaged in the business of developing, manufacturing and marketing generic drugs for the ethical (prescription) and over-the-counter (non-prescription) markets. The Company`s present product portfolio includes 14 prescription products in 23 strengths in 47 package sizes. The Company develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

JS200

[js200]

Caraco Pharmaceutical Laboratories Receives FDA Approval For Mirtazapine; Formulary Rises to 18 Drugs; Three Drugs Pending FDA Approval
via COMTEX

April 23, 2004

DETROIT, Apr 23, 2004 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market Mirtazapine, a generic form of Organon`s Remeron, Jitendra N. Doshi, Chief Executive Officer, announced today.

Mirtazapine tablets are indicated for the treatment of major depressive disorders and have a U.S. market potential of approximately $250 million.

The Company has received approval for a unique additional strength of 7.5 mg for the product, apart from regular 15, 30 &45 mg strengths. The product will be launched shortly.

Mr. Doshi added that the formulary of total products has increased to 18, with 35 strengths in 82 pack sizes. The Company now has three drugs pending FDA approval.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include: that the information is of a preliminary nature and may be subject to further adjustment; not obtaining FDA approval for new products or delays in receiving FDA approvals; governmental restrictions on the sale of certain products; dependence on key personnel; development by competitors of new or superior products or cheaper products or new technology for the production of products or the entry into the market of new competitors; market and customer acceptance and demand for new pharmaceutical products; availability of raw materials in a timely manner, at competitive prices, and in required quantities; timing and success of product development and launch; integrity and reliability of the Company`s data; lack of success in attaining full compliance with regard to regulatory and cGMP compliance; experiencing difficulty in managing our recent rapid growth and anticipated future growth; dependence on limited customer base; occasional credits to certain customers reflecting price reductions on products previously sold to them and still available as shelf-stock; possibility of an incorrect estimate of charge-backs and the impact of such an incorrect estimate on net sales, gross profit and net income; dependence on few products generating majority of sales; product liability claims for which the Company may be inadequately insured; subjectivity in judgment of management in applying certain significant accounting policies derived based on historical experience, terms of contracts, our observations of trends of industry, information received from our customers and other sources, to estimate revenues, accounts receivable, allowances including chargebacks, rebates, income taxes, values of assets and inventories etc. and other risks identified in this report and identified from time to time in our reports and registration statements filed with the Securities and Exchange Commission. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Jitendra Doshi or Bob Kurkiewicz of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CPD)

Copyright (C) 2004 PR Newswire. All rights reserved.


js200

[js200]

Last Trade: N/A Change: 0.000 (+0.000%)
Previous Close: 11.630 Volume: 0
Bid: N/A Ask: N/A
Today`s Open: N/A # of Trades: N/A

JS200

[js200]

04/28/2004 (14:03 ET) CPD: Q1 Results (9c) vs 9c; EPS -200% Y/Y; Provides Guidance - Knobias
04/28/2004 (14:00 ET) Caraco Pharmaceutical Posts Q1 Net Sales of $13.6 Million (Up 56%), Q1 Net Cash from Operating Activities of $6.2 Million, Net Loss of $2.2 Million, Non-Cash R&D Expense of $7.8 Million - PR Newswire
04/23/2004 (11:06 ET) CPD: Volume Spike; 18% > 20-adsv, Stock +3.48% - Knobias
04/23/2004 (09:10 ET) StreetInsider Alert for CPD - Street Insider
04/23/2004 (09:07 ET) CPD: FDA Approval for Generic Remeron for Depression - Knobias


JS200

[js200]

Last Trade: 11.400 Change: -0.030 (-0.262%)
Previous Close: 11.430 Volume: 49,000
Bid: N/A Ask: N/A
Today`s Open: 11.430 # of Trades: 121

05/20/2004 (16:14 ET) CPD: Short Interest UP 32.1% to 27.0K in May 2004 - Knobias
05/11/2004 (06:55 ET) INDUSTRY: Merrill Discusses Performance of Drug Wholesalers - Knobias
05/10/2004 (12:04 ET) CPD: Volume Spike; 21% > 20-adsv, Stock -11.60% - Knobias
04/30/2004 (15:44 ET) CPD: Filed New Form 10-Q - Edgar
04/30/2004 (15:04 ET) CPD: Filed 8-K Regarding 1st Qtr Results (Apr-28 PR) - Knobias

JS200

[js200]

Caraco Pharmaceutical Posts Mid-Year Net Sales $28.4 Million (Up 38%), Q2 Net Sales $14.8 Million (Up 24%), Six-Months Net Cash From Operations $8.8 Million, Six-Months Non-Cash R&D Expense $12.5 Million, Mid-Year Net Loss $0.7 Million
via COMTEX

July 20, 2004

DETROIT, Jul 20, 2004 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) posted strong mid-year and second quarter net sales of $28.4 million and $14.8 million, respectively, and generated record net cash from operations of $8.8 million. After mid-year non-cash R&D expense of $12.5 million, the net loss was $0.7 million, Jitendra N. Doshi, Chief Executive Officer, reported today.

Six-month 2004 results

H1-2004 net sales improved 38% to $28.4 million, from H1-2003 net sales of $20.6 million. The H1-2004 gross profit of $17.3 million, up 44%, compared favorably to H1-2003 gross profit of $12.0 million. Gross profit as a percentage of net sales improved marginally, to 61% in H1-2004, from 58% in the corresponding period of 2003.

Mr. Doshi said, "We incurred substantially higher total R&D expense for H1-2004 as three products were successfully transferred from Sun Global under the R&D agreement. Total R&D expenses for the period were $15.0 million, of which non-cash R&D expense was $12.5 million. This was considerably higher than $1.5 million and zero, respectively, for the corresponding period in 2003. This resulted in a net loss of $0.7 million or $(0.03) per diluted share for H1-2004, compared to a net income of $6.5 million, or $0.26 per diluted share for H1-2003.

"However, net cash generated from operations, which stood at $15.5 million for the full year of 2003 and $8.8 million for H1-2004, helped us to repay long-term loans, fund our expansion activities and augment working capital. During the six months, we utilized the cash accruals to repay the ICICI Bank loan of $4.4 million and the EDC loan of $6.4 million, make a scheduled repayment of $3.1 million to Bank of Nova Scotia and invest $2.5 million in facility upgrades. This was after available cash of $3.5 million and $1.5 million, utilized for increase in inventories and receivables, respectively."

Q2 results

Q2-2004 net sales rose 24% to $14.8 million, from net sales of $11.9 million in the corresponding period in Q2-2003. Gross profit for Q2-2004 was $9.1 million, up 21% over gross profit of $7.5 million for Q2-2003. Net income during Q2-2004 was $1.5 million, or $0.05 per diluted share, compared to net income of $4.3 million, or $0.17 per diluted share in Q2-2003. The lower income during Q2-2004 was primarily due to substantially higher R&D expenses for Q2-2004 of $6.0 million, of which non-cash R&D expense related to technology transfer was $4.7 million. In Q2-2003, because there were no product transfers, total R&D expense and non-cash R&D expense was $0.6 million and zero, respectively.

Mr. Doshi added, "We expect the healthy increase in sales and cash flow during the first half of 2004 to continue through the remainder of the year. However, pricing pressures, due to increased competition, which resulted in lower gross margins in the fourth quarter of 2003, are expected to remain in 2004. Nevertheless we are optimistic about achieving our previously stated guidance of 20-25% revenue growth for 2004."

"We continue to work aggressively to build our pipeline of products for our future growth. We have selected a total of 15 products out of 25, including 8 selected during Q2-2004, under the products agreement with Sun Global. These are at various stages of development. Of these 15 products, four have passed bio-equivalency studies. We have filed three ANDAs during H1-2004 and to date, four products are pending approval with the FDA. We hope to file six or seven ANDAs with the FDA in 2004, including the three already filed in H1-2004."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include: that the information is of a preliminary nature and may be subject to further adjustment; not obtaining FDA approval for new products or delays in receiving FDA approvals; governmental restrictions on the sale of certain products; dependence on key personnel; development by competitors of new or superior products or cheaper products or new technology for the production of products or the entry into the market of new competitors; market and customer acceptance and demand for new pharmaceutical products; availability of raw materials in a timely manner, at competitive prices, and in required quantities; timing and success of product development and launch; integrity and reliability of the Company`s data; lack of success in attaining full compliance with regard to regulatory and cGMP compliance; experiencing difficulty in managing our recent rapid growth and anticipated future growth; dependence on limited customer base; occasional credits to certain customers reflecting price reductions on products previously sold to them and still available as shelf-stock; possibility of an incorrect estimate of charge-backs and the impact of such an incorrect estimate on net sales, gross profit and net income; dependence on few products generating majority of sales; product liability claims for which the Company may be inadequately insured; subjectivity in judgment of management in applying certain significant accounting policies derived based on historical experience, terms of contracts, our observations of trends of industry, information received from our customers and other sources, to estimate revenues, accounts receivable, allowances including charge backs, rebates, income taxes, values of assets and inventories and other risks identified in this report and identified from time to time in our reports and registration statements filed with the Securities and Exchange Commission. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

CARACO PHARMACEUTICAL LABORATORIES, LTD. UNAUDITED STATEMENTS OF OPERATIONS SIX MONTHS ENDED THREE MONTHS ENDED JUNE 30 JUNE 30 2004 2003 2004 2003 Net sales 28,360,953 20,611,537 14,799,865 11,889,937 Cost of Goods Sold 11,111,175 8,653,413 5,720,474 4,427,464 Gross Profit 17,249,777 11,958,124 9,079,391 7,462,473 Selling, general & administrative expenses 2,693,078 3,089,820 1,410,723 2,140,036 R&D cost to affiliate - non-cash 12,491,600 0 4,663,440 0 R&D cost other 2,493,830 1,526,719 1,360,500 626,788 Operating (loss) / income (428,731) 7,341,585 1,644,729 4,695,649 Other Income / (expense) Interest expense (317,175) (817,722) (135,633) (375,470) Interest income 16,625 7,043 14,610 5,978 Other income 13,035 - 2,968 - Net other expense (287,515) (810,679) (118,055) (369,492) Net (loss) / income (716,246) 6,530,906 1,526,674 4,326,157 Net income / (loss) per basic common share (0.03) 0.27 0.06 0.18 Net income / (loss) per basic and diluted common share (0.03) 0.26 0.05 0.17 Schedule of Net Cash Provided By / (Used) in Operating Activities (Unaudited) (1) Six-month period ended 06/30/04 06/30/03 Net (loss) / income (716,246) 6,530,906 Adjustments to reconcile net (loss) / income to net cash provided by / (used) in operating activities Depreciation 413,749 316,261 Common shares issued in lieu of cash for compensation 0 32,450 Variable compensation expense for stock options 0 851,800 Preferred shares issued to affiliate for R&D Cost 12,491,600 0 Changes in operating assets and liabilities which provided / (used) cash Accounts receivable (1,490,092) (3,914,949) Inventories (3,494,344) 375,536 Prepaid expenses and deposits 154,372 (441,715) Accounts payable 1,911,514 68,467 Accrued expenses and Interest (499,854) (106,615) Net cash provided by operating activities 8,770,699 3,712,141
(1) This schedule of net cash provided by / (used) in operating activities is deemed by management to be a meaningful measure of financial performance and liquidity, and provides investors with a measure of cash that may be used for debt service and for other purposes.


SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Jitendra Doshi or Bob Kurkiewicz of Caraco Pharmaceutical Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CPD)


JS200

[js200]

Und wieder gehts Richtung Norden, macht immer wieder Freude

Last Trade: 7.140 Change: 0.120 (+1.709%)
Previous Close: 7.020 Volume: 17,500
Bid: N/A Ask: N/A
Today`s Open: 6.990 # of Trades: 57


JS200

[js200]

09/16/2004 (11:05 ET) CPD: Filed New Form RW - Edgar
08/19/2004 (16:14 ET) CPD: Short Interest DN 10.2% to 107.8K in Aug 2004 - Knobias

JS200

[js200]

Last Trade: 7.900 Change: 0.200 (+2.597%)
Previous Close: 7.700 Volume: 42,300
Bid: N/A Ask: N/A
Today`s Open: 7.780 # of Trades: 92

[js200]

Last Trade: 7.350 Change: 0.030 (+0.410%)
Previous Close: 7.320 Volume: 15,400
Bid: N/A Ask: N/A
Today`s Open: 7.310 # of Trades: 47

[js200]

10/20/2004 (06:50 ET) TABLE: Unconfirmed Earnings Expected Wednesday, Oct 20 - Knobias
09/21/2004 (16:14 ET) CPD: Short Interest DN 11.2% to 95.7K in Sep 2004 - Knobias

JS200

[js200]

Caraco Pharmaceutical Posts 9-Month Net Sales $43.7 Million (Up 33%), Q3 Net Sales $15.3 Million (Up 24%), 9-Month Net Cash From Operations $16.9 Million, 9-Month Non-Cash R&D Expense $18.2 Million, 9-Month Net Income $0.3 Million, Diluted EP
via COMTEX

October 20, 2004

DETROIT, Oct 20, 2004 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) posted strong 9-month and third quarter net sales of $43.7 million and $15.3 million, respectively, and generated record net cash from operations of $16.9 million. After 9-month non-cash R&D expense of $18.2 million, net income was $0.3 million, Jitendra N. Doshi, Chief Executive Officer, reported today.

Nine-month 2004 results

Nine-month 2004 net sales improved 33% to $43.7 million, from $32.9 million during the corresponding period of 2003. The nine-month 2004 gross profit of $26.5 million, up 34%, compared favorably to nine-month 2003 gross profit of $19.8 million. Gross profit as a percentage of net sales improved marginally to 61% for the nine-months ended September 30, 2004, from 60% in the corresponding period of 2003.

Mr. Doshi said, "We incurred substantially higher total R&D expense for nine-month 2004 as five products were successfully transferred from Sun Global under the R&D agreement. Total R&D expenses for the period were $22.2 million, of which non-cash R&D expense was $18.2 million. This was considerably higher than $2.0 million and zero, respectively, for the corresponding period in 2003. This resulted in a nominal net income of $0.3 million or $0.01 per diluted share for nine-month 2004, compared to a net income of $11.1 million, or $0.44 per diluted share for nine-month 2003."

"Net cash generated from operations was $16.9 million for nine-months 2004, up from $9.4 million for the corresponding period in 2003. This, and a new lower-cost loan of $10.0 million from Citibank, helped us to repay long- term loans, fund our expansion activities and augment working capital."

"During the nine-months 2004, we utilized the available cash to fully repay the ICICI Bank loan of $4.4 million, the EDC loan of $6.4 million, and the Bank of Nova Scotia loan of $12.5 million. We also invested $3.0 million in facility upgrades and $5.1 million to increase inventories and repaid $3.0 million to Citibank."

"As a result, the total outstanding debt as of September 30, 2004 has been reduced to $7.0 million, down from $27.2 million as of September 30, 2003."

Q3 results

Q3-2004 net sales rose 24% to $15.3 million, from net sales of $12.3 million in the corresponding period in Q3-2003. Gross profit for Q3-2004 was $9.3 million, up 19% over gross profit of $7.8 million for Q3-2003. Net income during Q3-2004 was $1.1 million, or $0.04 per diluted share, compared to net income of $4.5 million, or $0.18 per diluted share in Q3-2003. The lower income for Q3-2004 was primarily due to substantially higher R&D expenses of $7.2 million, of which non-cash R&D expense related to technology transfers was $5.7 million. This was considerably higher than $0.5 million and zero, respectively, for the corresponding period in 2003.

Mr. Doshi added, "We expect the healthy increase in sales and cash flow from operations during the first nine months of 2004 to continue through the remainder of the year. Pricing pressures, due to increased competition, have continued during 2004 and are expected to continue in 2005, which may result in lower gross margins. Management has and will continue to work diligently to counter the pricing pressures through increased sales volumes, better-cost absorption of operational overheads, and cost reductions. We are optimistic to achieve the higher of our previously stated guidance of 20% to 25% revenue growth during 2004."

"We continue to work aggressively to build our pipeline of products for our future growth. We have selected a total of 15 products out of 25 under the products agreement with Sun Global. These are at various stages of development. Of these 15 products, six have passed bio-equivalency studies. We have filed three ANDAs during the nine months of 2004 and, to date, four products are pending approval with the FDA. We hope to file three or four additional ANDAs with the FDA during the remainder of 2004."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation`s largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include: that the information is of a preliminary nature and may be subject to further adjustment; not obtaining FDA approval for new products or delays in receiving FDA approvals; governmental restrictions on the sale of certain products; dependence on key personnel; development by competitors of new or superior products or cheaper products or new technology for the production of products or the entry into the market of new competitors; market and customer acceptance and demand for new pharmaceutical products ; availability of raw materials in a timely manner, at competitive prices, and in required quantities; timing and success of product development and launch; integrity and reliability of the Company`s data; lack of success in attaining full compliance with regard to regulatory and cGMP compliance; experiencing difficulty in managing our recent rapid growth and anticipated future growth; dependence on limited customer base; occasional credits to certain customers reflecting price reductions on products previously sold to them and still available as shelf-stock; possibility of an incorrect estimate of charge-backs and the impact of such an incorrect estimate on net sales, gross profit and net income; dependence on few products generating majority of sales; product liability claims for which the Company may be inadequately insured; subjectivity in judgment of management in applying certain significant accounting policies derived based on historical experience, terms of contracts, our observations of trends of industry, information received from our customers and other sources, to estimate revenues, accounts receivable, allowances including charge-backs, rebates, income taxes, values of assets and inventories and other risks identified in this report and identified from time to time in our reports and registration statements filed with the Securities and Exchange Commission. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

CARACO PHARMACEUTICAL LABORATORIES, LTD. UNAUDITED STATEMENTS OF OPERATIONS NINE MONTHS ENDED THREE MONTHS ENDED SEPTEMBER 30 SEPTEMBER 30 2004 2003 2004 2003 $ $ $ $ Net sales 43,659,631 32,905,662 15,298,678 12,294,125 Cost of Goods Sold 17,157,588 13,112,198 6,046,413 4,458,785 Gross Profit 26,502,043 19,793,465 9,252,265 7,835,341 Selling, general & administrative expenses 3,576,514 5,689,566 883,436 2,599,746 R&D cost to affiliate - non-cash 18,179,120 - 5,687,520 - R&D cost other 4,037,282 2,018,029 1,543,452 491,310 Operating income 709,127 12,085,870 1,137,857 4,744,285 Other Income / (expense) Interest expense (398,672) (1,041,382) (81,497) (223,660) Interest income 34,767 24,790 18,142 17,747 Other income / (loss) 617 - (12,417) - Net other expense (363,288) (1,016,593) (75,773) (205,914) Net income 345,839 11,069,277 1,062,084 4,538,371 Net income per basic common share 0.01 0.46 0.04 0.19 Net income per basic and diluted common share 0.01 0.44 0.04 0.18 Number of: Basic common share 24,583,220 23,977,673 24,583,220 23,977,673 Basic and diluted common shares 29,318,828 25,317,464 29,318,828 25,317,464 Schedule of Net Cash Provided By Operating Activities (Unaudited) (1) Nine-month period ended 09/30/04 09/30/03 $ $ Net income 345,839 11,069,277 Adjustments to reconcile net income to net cash provided by / (used) in operating activities Depreciation 615,917 422,179 Common shares issued in lieu of cash for compensation 0 262,450 Variable compensation expense for stock options 0 1,833,612 Preferred shares issued to affiliate for R&D Cost 18,179,120 0 Changes in operating assets and liabilities which provided / (used) cash Accounts receivable 2,815,065 (925,503) Inventories (5,086,949) (1,867,348) Prepaid expenses and deposits (706,714) (1,004,969) Accounts payable 1,108,980 (648,115) Accrued expenses and Interest (385,971) 210,663 Net cash provided by operating activities 16,885,287 9,352,247
(1) This schedule of net cash provided by operating activities is deemed by management to be a meaningful measure of financial performance and liquidity, and provides investors with a measure of cash that may be used for debt service and for other purposes.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Jitendra Doshi or Bob Kurkiewicz of Caraco Pharmaceutical Laboratories, Ltd., [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. (CPD)

Copyright (C) 2004 PR Newswire. All rights reserved.

[js200]

10/21/2004 (17:01 ET) CPD: Filed New Form 10-Q - Edgar
10/21/2004 (16:14 ET) CPD: Short Interest UP 1.9% to 97.5K in Oct 2004 - Knobias
10/20/2004 (11:06 ET) CPD: Filed 8-K Regarding 3rd Qtr Results (Oct-20 PR) - Knobias
10/20/2004 (11:04 ET) CPD: Filed New Form 8-K - Edgar
10/20/2004 (10:48 ET) CPD: Filed New Form 8-K - Edgar

[js200]

11/15/2004 (10:56 ET) CPD: Volume Spike; 87% > 20-adsv, Stock +2.40% - Knobias
11/15/2004 (09:10 ET) CPD: Receives FDA Approval Citalopram Hydrobromide Tablets - Knobias
11/15/2004 (09:01 ET) Caraco Pharmaceutical Laboratories Receives FDA Approval for Citalopram Hydrobromide Tablets - PR Newswire
11/08/2004 (14:25 ET) CPD: Volume Spike; 140% > 20-adsv, Stock -3.26% - Knobias
11/02/2004 (08:35 ET) SECTOR: M Stanley Sees Near Term Risks in Pharma Group - Knobias

[js200]

11/19/2004 (17:43 ET) CPD: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/19/2004 (16:13 ET) CPD: Short Interest DN 19.0% to 79.0K in Nov 2004 - Knobias
11/19/2004 (13:29 ET) CPD: Filed New Form SC 13D/A, Beneficial Ownership Disclosure - Knobias
11/17/2004 (16:10 ET) CPD: New Form 4 Filed, Change in Beneficial Ownership - Knobias
11/17/2004 (09:09 ET) SECTOR: M Stanley Sees Strong Growth in Respiratory Drug Mkt - Knobias

[js200]

SECTOR: Raymond Sees Consolidation in Generic Drug Industry

Monday , November 22, 2004 09:14 ET

Raymond James commented that Carl Icahn`s November 19 bid for MYL suggests that ADRX and WPI are vastly undervalued. Icahn`s $20/share bid for Mylan implies an enterprise value of about 3.9x revenue. By comparison, WPI sells for about 2x revenue while ADRX sells for about 1.4x revenue (after backing out its lower-margin distribution business). The firm thinks that Icahn is unlikely to purchase MYL and will likely sell his shares to another generic drug company, probably TEVA or NVS.

Raymond James believes a sale of MYL will likely spur consolidation. They think generic drug companies must merge to stem a flood of supply of generic drugs that is depressing prices. The firm favors both ADRX and WPI because low valuation limits potential declines in their shares while investors wait for the companies to either get sold or win approvals of generic drugs.

They reiterated their Underperform rating on TEVA amid their belief that increased supply of generic drugs will hinder its efforts to meet lofty expectations. They believe Teva will acquire its way out of the industry`s problems, potentially diluting shareholders.

Public Companies Associated with this story:
ABLE LABORATORIES INC (NASDAQ NM: ABRX) ANDRX CORPORATION (NASDAQ NM: ADRX) BARR PHARMACEUTICALS, INC. (NYSE: BRL)
CARACO PHARMACEUTICAL LABS LTD (AMEX: CPD) GENVEC, INCORPORATED (NASDAQ NM: GNVC) HI-TECH PHARMACAL CO., INC. (NASDAQ NM: HITK)
ISOLAGEN INC (AMEX: ILE) INTERPHARM HOLDINGS, INC. (AMEX: IPA) IMPAX LABORATORIES INCORPORATED (NASDAQ NM: IPXL)
IVAX CORP (AMEX: IVX) MYLAN LABORATORIES INC. (NYSE: MYL) NOVARTIS AG ADS (NYSE: NVS)
PRO-PHARMACEUTICALS INC (AMEX: PRW) PAR PHARMACEUTICAL COMPANIES, INC. (NYSE: PRX) SERACARE LIFE SCIENCES, INCORPORATE (NASDAQ NM: SRLS)
TEVA PHARMACEUTICAL INDUSTRIES LTD (NASDAQ NM: TEVA) WATSON PHARMACEUTICALS INC (NYSE: WPI)

[js200]

Last Trade: 7.690 Change: 0.360 (+4.911%)
Previous Close: 7.330 Volume: 36,700
Bid: N/A Ask: N/A
Today`s Open: 7.390 # of Trades: 69

[MaatMod]

Auf Grund des Diskussionsbedarfes schalte ich den historischen Thread frei.

[js200]

Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval For Generic Coreg(R) Tablets
via COMTEX

January 31, 2006

DETROIT, Jan 31, 2006 /PRNewswire-FirstCall via COMTEX/ --

Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the U.S. Food and Drug Administration (FDA) have granted tentative approval for the Company`s ANDA for the remaining strengths of Carvedilol tablets. Final approval of this product is anticipated subsequent to the expiry of patent protection in March 2007.

Caraco`s Carvedilol 6.25mg, 12.5mg and 25mg tablets are the generic equivalent of GlaxoSmithKline`s Coreg(R), which is indicated for the treatment of mild to severe heart failure of ischemic or cardiomyopathic origin. It is also indicated to reduce cardiovascular mortality and for the management of essential hypertension.

"With these three additional strengths we now have tentative approval on all currently marketed strengths of Carvedilol, our generic equivalent to Coreg(R). We look forward to the expiration date of the patent for these particular strengths, 6.25mg, 12.5mg and 25mg in March of 2007, allowing Caraco to market the product at that point in time," said Daniel H. Movens, Chief Executive Officer. "Once the patent expires and we are allowed to launch these particular strengths we believe that this product will be a nice addition that will only complement our growing portfolio of approved products already marketed."

Total annual U.S. sales of the brand product for these particular strengths of Carvedilol for all indications are approximately $900 million.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to the nation`s wholesalers, distributors, drugstore chains and healthcare systems.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management`s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties are contained in the Corporation`s filings with the Securities and Exchange Commission and include: information is of a preliminary nature and may be subject to adjustment, not obtaining or delays in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, dependence on key personnel, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, integrity and reliability of the Corporation`s data, lack of success of attaining full compliance with regard to regulatory and cGMP compliance, experiencing difficulty in managing our recent rapid growth and anticipated future growth, dependence on limited customer base, occasional credits to certain customers reflecting price reductions on products previously sold to them and still available as shelf- stock, possibility of an incorrect estimate of charge-backs and the impact of such an incorrect estimate on net sales, gross profit and net income, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, subjectivity in judgment of management in applying certain significant accounting policies derived based on historical experience, terms of contracts, our observations of trends of industry, information received from our customers and other sources, to estimate revenues, accounts receivable allowances including chargebacks, rebates, income taxes, values of assets and inventories, litigation involving claims of patent infringement, litigation involving claims for royalties relating to a prior contract for one product and other risks identified in this report and identified from time to time in our reports and registration statements filed with the Securities and Exchange Commission. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.

Daniel Movens or Jitendra Doshi of Caraco Pharmaceutical, [phone]; or Mike Marcotte of Marcotte Financial Relations, [phone], for Caraco Pharmaceutical Laboratories, Ltd. http://www.prnewswire.com

Copyright (C) 2006 PR Newswire. All rights reserved.

Print story

Current Quote

AMX: CPD
Drugs - Generic

Last: 11.710
Change: -0.130
Volume: 73,300
Day High: 11.950
Day Low: 11.510



First Alert News
Get real-time CPD release alerts by entering your email address below.